<?xml version="1.0" encoding="UTF-8"?>

<Bundle xmlns="http://hl7.org/fhir">
  <id value="995d3971-b899-43bf-857d-98c26634796d"/>
  <meta>
    <versionId value="1"/>
    <lastUpdated value="2021-06-25T22:39:35.186+00:00"/>
  </meta>
  <identifier>
    <system value="http://ema.europa.eu/fhir/identifier/documentid"/>
    <value value="3103a561-4b54-4e02-9cd0-eceb190a0602"/>
  </identifier>
  <type value="document"/>
  <timestamp value="2021-06-25T22:39:32+00:00"/>
  <entry>
    <fullUrl value="urn:uuid:be0cf64a-79ae-427b-bd11-06e24f7798ab"/>
    <resource>
      <Composition>
        <language value="no"/>
        <text>
          <status value="generated"/><div xmlns="http://www.w3.org/1999/xhtml" xml:lang="no" lang="no"><p><b>Generated Narrative</b></p><p><b>status</b>: final</p><p><b>type</b>: <span title="Codes: {http://spor.ema.europa.eu/v1/lists/100000155531 100000155532}">PREPARATOMTALE</span></p><p><b>date</b>: 2021-02-01</p><p><b>author</b>: <span></span></p><p><b>title</b>: Acme Product</p><h3>RelatesTos</h3><table class="grid"><tr><td>-</td><td><b>Code</b></td><td><b>Target[x]</b></td></tr><tr><td>*</td><td>appends</td><td><a href="${document[n].relatesTo}">${document[n].relatesTo}</a></td></tr></table></div>
        </text>
        <contained>
          <Binary>
            <id value="stylesheet0"/>
            <contentType value="stylesheet/css"/>
            <data value="<style>
<!--
 /* Font Definitions */
 @font-face
	{font-family:Wingdings;
	panose-1:5 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"MS Mincho";
	panose-1:2 2 6 9 4 2 5 8 3 4;}
@font-face
	{font-family:SimSun;
	panose-1:2 1 6 0 3 1 1 1 1 1;}
@font-face
	{font-family:"Cambria Math";
	panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
	{font-family:Calibri;
	panose-1:2 15 5 2 2 2 4 3 2 4;}
@font-face
	{font-family:"Calibri Light";
	panose-1:2 15 3 2 2 2 4 3 2 4;}
@font-face
	{font-family:Verdana;
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:"Segoe UI";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"\@SimSun";
	panose-1:2 1 6 0 3 1 1 1 1 1;}
@font-face
	{font-family:"\@MS Mincho";
	panose-1:2 2 6 9 4 2 5 8 3 4;}
 /* Style Definitions */
 p.MsoNormal, li.MsoNormal, div.MsoNormal
	{margin:0in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
h1
	{mso-style-link:"Heading 1 Char";
	margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:70.85pt;
	text-align:justify;
	text-justify:inter-ideograph;
	text-indent:-70.85pt;
	page-break-after:avoid;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	text-transform:uppercase;
	font-weight:bold;}
h2
	{mso-style-link:"Heading 2 Char";
	margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:70.85pt;
	text-align:justify;
	text-justify:inter-ideograph;
	text-indent:-70.85pt;
	page-break-after:avoid;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
h3
	{mso-style-link:"Heading 3 Char";
	margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:70.85pt;
	text-align:justify;
	text-justify:inter-ideograph;
	text-indent:-70.85pt;
	page-break-after:avoid;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
h4
	{mso-style-link:"Heading 4 Char";
	margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:70.85pt;
	text-align:justify;
	text-justify:inter-ideograph;
	text-indent:-70.85pt;
	page-break-after:avoid;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
h5
	{mso-style-link:"Heading 5 Char";
	margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:70.85pt;
	text-indent:-70.85pt;
	page-break-after:avoid;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
h6
	{mso-style-link:"Heading 6 Char";
	margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:70.85pt;
	text-indent:-70.85pt;
	page-break-after:avoid;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.MsoHeading7, li.MsoHeading7, div.MsoHeading7
	{mso-style-link:"Heading 7 Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:21.25pt;
	text-indent:-21.25pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoHeading8, li.MsoHeading8, div.MsoHeading8
	{mso-style-link:"Heading 8 Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:42.5pt;
	text-indent:-21.25pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoHeading9, li.MsoHeading9, div.MsoHeading9
	{mso-style-link:"Heading 9 Char";
	margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Calibri Light",sans-serif;}
p.MsoIndex1, li.MsoIndex1, div.MsoIndex1
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:11.0pt;
	text-indent:-11.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoIndex2, li.MsoIndex2, div.MsoIndex2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:22.0pt;
	text-indent:-11.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoIndex3, li.MsoIndex3, div.MsoIndex3
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:33.0pt;
	text-indent:-11.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoIndex4, li.MsoIndex4, div.MsoIndex4
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:44.0pt;
	text-indent:-11.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoIndex5, li.MsoIndex5, div.MsoIndex5
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:55.0pt;
	text-indent:-11.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoIndex6, li.MsoIndex6, div.MsoIndex6
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:66.0pt;
	text-indent:-11.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoIndex7, li.MsoIndex7, div.MsoIndex7
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:77.0pt;
	text-indent:-11.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoIndex8, li.MsoIndex8, div.MsoIndex8
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:88.0pt;
	text-indent:-11.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoIndex9, li.MsoIndex9, div.MsoIndex9
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:99.0pt;
	text-indent:-11.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc1, li.MsoToc1, div.MsoToc1
	{margin:0in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc2, li.MsoToc2, div.MsoToc2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:11.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc3, li.MsoToc3, div.MsoToc3
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:22.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc4, li.MsoToc4, div.MsoToc4
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:33.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc5, li.MsoToc5, div.MsoToc5
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:44.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc6, li.MsoToc6, div.MsoToc6
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:55.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc7, li.MsoToc7, div.MsoToc7
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:66.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc8, li.MsoToc8, div.MsoToc8
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:77.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc9, li.MsoToc9, div.MsoToc9
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:88.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoNormalIndent, li.MsoNormalIndent, div.MsoNormalIndent
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoFootnoteText, li.MsoFootnoteText, div.MsoFootnoteText
	{mso-style-link:"Footnote Text Char";
	margin:0in;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
p.MsoCommentText, li.MsoCommentText, div.MsoCommentText
	{mso-style-name:"Comment Text\,Car17\,Car17 Car\,Car17 Car Car\,Char13\,Char13 Car\,Char13 Car Car";
	mso-style-link:"Comment Text Char\,Car17 Char\,Car17 Car Char\,Car17 Car Car Char\,Char13 Char\,Char13 Car Char\,Char13 Car Car Char";
	margin:0in;
	line-height:13.0pt;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
p.MsoHeader, li.MsoHeader, div.MsoHeader
	{mso-style-link:"Header Char";
	margin:0in;
	line-height:13.0pt;
	font-size:10.0pt;
	font-family:"Arial",sans-serif;}
p.MsoFooter, li.MsoFooter, div.MsoFooter
	{mso-style-link:"Footer Char";
	margin:0in;
	line-height:13.0pt;
	font-size:8.0pt;
	font-family:"Arial",sans-serif;}
p.MsoIndexHeading, li.MsoIndexHeading, div.MsoIndexHeading
	{margin:0in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Calibri Light",sans-serif;
	font-weight:bold;}
p.MsoCaption, li.MsoCaption, div.MsoCaption
	{mso-style-name:"Caption\,Caption 12pt\,Caption 12pt+\,Caption-FUSA\,figure";
	margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:0in;
	text-align:center;
	page-break-after:avoid;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.MsoTof, li.MsoTof, div.MsoTof
	{margin:0in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoEnvelopeAddress, li.MsoEnvelopeAddress, div.MsoEnvelopeAddress
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:2.0in;
	line-height:13.0pt;
	font-size:12.0pt;
	font-family:"Calibri Light",sans-serif;}
p.MsoEnvelopeReturn, li.MsoEnvelopeReturn, div.MsoEnvelopeReturn
	{margin:0in;
	line-height:13.0pt;
	font-size:10.0pt;
	font-family:"Calibri Light",sans-serif;}
span.MsoCommentReference
	{font-family:"Times New Roman",serif;}
span.MsoPageNumber
	{font-family:"Times New Roman",serif;}
p.MsoEndnoteText, li.MsoEndnoteText, div.MsoEndnoteText
	{mso-style-link:"Endnote Text Char";
	margin:0in;
	line-height:13.0pt;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToa, li.MsoToa, div.MsoToa
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:11.0pt;
	text-indent:-11.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoMacroText, li.MsoMacroText, div.MsoMacroText
	{mso-style-link:"Macro Text Char";
	margin:0in;
	line-height:13.0pt;
	font-size:10.0pt;
	font-family:"Courier New";}
p.MsoToaHeading, li.MsoToaHeading, div.MsoToaHeading
	{margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:0in;
	line-height:13.0pt;
	font-size:12.0pt;
	font-family:"Calibri Light",sans-serif;
	font-weight:bold;}
p.MsoList, li.MsoList, div.MsoList
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:14.15pt;
	text-indent:-14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListCxSpFirst, li.MsoListCxSpFirst, div.MsoListCxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:14.15pt;
	text-indent:-14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListCxSpMiddle, li.MsoListCxSpMiddle, div.MsoListCxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:14.15pt;
	text-indent:-14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListCxSpLast, li.MsoListCxSpLast, div.MsoListCxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:14.15pt;
	text-indent:-14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet, li.MsoListBullet, div.MsoListBullet
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBulletCxSpFirst, li.MsoListBulletCxSpFirst, div.MsoListBulletCxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBulletCxSpMiddle, li.MsoListBulletCxSpMiddle, div.MsoListBulletCxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBulletCxSpLast, li.MsoListBulletCxSpLast, div.MsoListBulletCxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber, li.MsoListNumber, div.MsoListNumber
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumberCxSpFirst, li.MsoListNumberCxSpFirst, div.MsoListNumberCxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumberCxSpMiddle, li.MsoListNumberCxSpMiddle, div.MsoListNumberCxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumberCxSpLast, li.MsoListNumberCxSpLast, div.MsoListNumberCxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList2, li.MsoList2, div.MsoList2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:28.3pt;
	text-indent:-14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList2CxSpFirst, li.MsoList2CxSpFirst, div.MsoList2CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:28.3pt;
	text-indent:-14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList2CxSpMiddle, li.MsoList2CxSpMiddle, div.MsoList2CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:28.3pt;
	text-indent:-14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList2CxSpLast, li.MsoList2CxSpLast, div.MsoList2CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:28.3pt;
	text-indent:-14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList3, li.MsoList3, div.MsoList3
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:42.45pt;
	text-indent:-14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList3CxSpFirst, li.MsoList3CxSpFirst, div.MsoList3CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:42.45pt;
	text-indent:-14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList3CxSpMiddle, li.MsoList3CxSpMiddle, div.MsoList3CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:42.45pt;
	text-indent:-14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList3CxSpLast, li.MsoList3CxSpLast, div.MsoList3CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:42.45pt;
	text-indent:-14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList4, li.MsoList4, div.MsoList4
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:56.6pt;
	text-indent:-14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList4CxSpFirst, li.MsoList4CxSpFirst, div.MsoList4CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:56.6pt;
	text-indent:-14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList4CxSpMiddle, li.MsoList4CxSpMiddle, div.MsoList4CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:56.6pt;
	text-indent:-14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList4CxSpLast, li.MsoList4CxSpLast, div.MsoList4CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:56.6pt;
	text-indent:-14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList5, li.MsoList5, div.MsoList5
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:70.75pt;
	text-indent:-14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList5CxSpFirst, li.MsoList5CxSpFirst, div.MsoList5CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:70.75pt;
	text-indent:-14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList5CxSpMiddle, li.MsoList5CxSpMiddle, div.MsoList5CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:70.75pt;
	text-indent:-14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList5CxSpLast, li.MsoList5CxSpLast, div.MsoList5CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:70.75pt;
	text-indent:-14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet2, li.MsoListBullet2, div.MsoListBullet2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet2CxSpFirst, li.MsoListBullet2CxSpFirst, div.MsoListBullet2CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet2CxSpMiddle, li.MsoListBullet2CxSpMiddle, div.MsoListBullet2CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet2CxSpLast, li.MsoListBullet2CxSpLast, div.MsoListBullet2CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet3, li.MsoListBullet3, div.MsoListBullet3
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.75in;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet3CxSpFirst, li.MsoListBullet3CxSpFirst, div.MsoListBullet3CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.75in;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet3CxSpMiddle, li.MsoListBullet3CxSpMiddle, div.MsoListBullet3CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.75in;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet3CxSpLast, li.MsoListBullet3CxSpLast, div.MsoListBullet3CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.75in;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet4, li.MsoListBullet4, div.MsoListBullet4
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:1.0in;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet4CxSpFirst, li.MsoListBullet4CxSpFirst, div.MsoListBullet4CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:1.0in;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet4CxSpMiddle, li.MsoListBullet4CxSpMiddle, div.MsoListBullet4CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:1.0in;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet4CxSpLast, li.MsoListBullet4CxSpLast, div.MsoListBullet4CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:1.0in;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet5, li.MsoListBullet5, div.MsoListBullet5
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:1.25in;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet5CxSpFirst, li.MsoListBullet5CxSpFirst, div.MsoListBullet5CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:1.25in;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet5CxSpMiddle, li.MsoListBullet5CxSpMiddle, div.MsoListBullet5CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:1.25in;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet5CxSpLast, li.MsoListBullet5CxSpLast, div.MsoListBullet5CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:1.25in;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber2, li.MsoListNumber2, div.MsoListNumber2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber2CxSpFirst, li.MsoListNumber2CxSpFirst, div.MsoListNumber2CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber2CxSpMiddle, li.MsoListNumber2CxSpMiddle, div.MsoListNumber2CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber2CxSpLast, li.MsoListNumber2CxSpLast, div.MsoListNumber2CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber3, li.MsoListNumber3, div.MsoListNumber3
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.75in;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber3CxSpFirst, li.MsoListNumber3CxSpFirst, div.MsoListNumber3CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.75in;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber3CxSpMiddle, li.MsoListNumber3CxSpMiddle, div.MsoListNumber3CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.75in;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber3CxSpLast, li.MsoListNumber3CxSpLast, div.MsoListNumber3CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.75in;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber4, li.MsoListNumber4, div.MsoListNumber4
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:1.0in;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber4CxSpFirst, li.MsoListNumber4CxSpFirst, div.MsoListNumber4CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:1.0in;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber4CxSpMiddle, li.MsoListNumber4CxSpMiddle, div.MsoListNumber4CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:1.0in;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber4CxSpLast, li.MsoListNumber4CxSpLast, div.MsoListNumber4CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:1.0in;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber5, li.MsoListNumber5, div.MsoListNumber5
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:1.25in;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber5CxSpFirst, li.MsoListNumber5CxSpFirst, div.MsoListNumber5CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:1.25in;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber5CxSpMiddle, li.MsoListNumber5CxSpMiddle, div.MsoListNumber5CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:1.25in;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber5CxSpLast, li.MsoListNumber5CxSpLast, div.MsoListNumber5CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:1.25in;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoTitle, li.MsoTitle, div.MsoTitle
	{mso-style-link:"Title Char";
	margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	text-align:center;
	line-height:13.0pt;
	font-size:16.0pt;
	font-family:"Calibri Light",sans-serif;
	font-weight:bold;}
p.MsoClosing, li.MsoClosing, div.MsoClosing
	{mso-style-link:"Closing Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:212.6pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoSignature, li.MsoSignature, div.MsoSignature
	{mso-style-link:"Signature Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:212.6pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoBodyText, li.MsoBodyText, div.MsoBodyText
	{mso-style-link:"Body Text Char";
	margin:0in;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
p.MsoBodyTextIndent, li.MsoBodyTextIndent, div.MsoBodyTextIndent
	{mso-style-link:"Body Text Indent Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue, li.MsoListContinue, div.MsoListContinue
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinueCxSpFirst, li.MsoListContinueCxSpFirst, div.MsoListContinueCxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinueCxSpMiddle, li.MsoListContinueCxSpMiddle, div.MsoListContinueCxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinueCxSpLast, li.MsoListContinueCxSpLast, div.MsoListContinueCxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue2, li.MsoListContinue2, div.MsoListContinue2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:28.3pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue2CxSpFirst, li.MsoListContinue2CxSpFirst, div.MsoListContinue2CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:28.3pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue2CxSpMiddle, li.MsoListContinue2CxSpMiddle, div.MsoListContinue2CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:28.3pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue2CxSpLast, li.MsoListContinue2CxSpLast, div.MsoListContinue2CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:28.3pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue3, li.MsoListContinue3, div.MsoListContinue3
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:42.45pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue3CxSpFirst, li.MsoListContinue3CxSpFirst, div.MsoListContinue3CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:42.45pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue3CxSpMiddle, li.MsoListContinue3CxSpMiddle, div.MsoListContinue3CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:42.45pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue3CxSpLast, li.MsoListContinue3CxSpLast, div.MsoListContinue3CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:42.45pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue4, li.MsoListContinue4, div.MsoListContinue4
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:56.6pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue4CxSpFirst, li.MsoListContinue4CxSpFirst, div.MsoListContinue4CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:56.6pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue4CxSpMiddle, li.MsoListContinue4CxSpMiddle, div.MsoListContinue4CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:56.6pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue4CxSpLast, li.MsoListContinue4CxSpLast, div.MsoListContinue4CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:56.6pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue5, li.MsoListContinue5, div.MsoListContinue5
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:70.75pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue5CxSpFirst, li.MsoListContinue5CxSpFirst, div.MsoListContinue5CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:70.75pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue5CxSpMiddle, li.MsoListContinue5CxSpMiddle, div.MsoListContinue5CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:70.75pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue5CxSpLast, li.MsoListContinue5CxSpLast, div.MsoListContinue5CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:70.75pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoMessageHeader, li.MsoMessageHeader, div.MsoMessageHeader
	{mso-style-link:"Message Header Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:56.7pt;
	text-indent:-56.7pt;
	line-height:13.0pt;
	background:#CCCCCC;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Calibri Light",sans-serif;}
p.MsoSubtitle, li.MsoSubtitle, div.MsoSubtitle
	{mso-style-link:"Subtitle Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	text-align:center;
	line-height:13.0pt;
	font-size:12.0pt;
	font-family:"Calibri Light",sans-serif;}
p.MsoSalutation, li.MsoSalutation, div.MsoSalutation
	{mso-style-link:"Salutation Char";
	margin:0in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoDate, li.MsoDate, div.MsoDate
	{mso-style-link:"Date Char";
	margin:0in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoBodyTextFirstIndent, li.MsoBodyTextFirstIndent, div.MsoBodyTextFirstIndent
	{mso-style-link:"Body Text First Indent Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:0in;
	text-indent:10.5pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoBodyTextFirstIndent2, li.MsoBodyTextFirstIndent2, div.MsoBodyTextFirstIndent2
	{mso-style-link:"Body Text First Indent 2 Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:14.15pt;
	text-indent:10.5pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoNoteHeading, li.MsoNoteHeading, div.MsoNoteHeading
	{mso-style-link:"Note Heading Char";
	margin:0in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoBodyText2, li.MsoBodyText2, div.MsoBodyText2
	{mso-style-link:"Body Text 2 Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:0in;
	line-height:200%;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoBodyText3, li.MsoBodyText3, div.MsoBodyText3
	{mso-style-link:"Body Text 3 Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:0in;
	line-height:13.0pt;
	font-size:8.0pt;
	font-family:"Times New Roman",serif;}
p.MsoBodyTextIndent2, li.MsoBodyTextIndent2, div.MsoBodyTextIndent2
	{mso-style-link:"Body Text Indent 2 Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:14.15pt;
	line-height:200%;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoBodyTextIndent3, li.MsoBodyTextIndent3, div.MsoBodyTextIndent3
	{mso-style-link:"Body Text Indent 3 Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:14.15pt;
	line-height:13.0pt;
	font-size:8.0pt;
	font-family:"Times New Roman",serif;}
p.MsoBlockText, li.MsoBlockText, div.MsoBlockText
	{margin-top:0in;
	margin-right:1.0in;
	margin-bottom:6.0pt;
	margin-left:1.0in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
a:link, span.MsoHyperlink
	{font-family:"Times New Roman",serif;
	color:blue;
	text-decoration:underline;}
a:visited, span.MsoHyperlinkFollowed
	{font-family:"Times New Roman",serif;
	color:purple;
	text-decoration:underline;}
p.MsoDocumentMap, li.MsoDocumentMap, div.MsoDocumentMap
	{mso-style-link:"Document Map Char";
	margin:0in;
	line-height:13.0pt;
	font-size:8.0pt;
	font-family:"Segoe UI",sans-serif;}
p.MsoPlainText, li.MsoPlainText, div.MsoPlainText
	{mso-style-link:"Plain Text Char";
	margin:0in;
	line-height:13.0pt;
	font-size:10.0pt;
	font-family:"Courier New";}
p.MsoAutoSig, li.MsoAutoSig, div.MsoAutoSig
	{mso-style-link:"E-mail Signature Char";
	margin:0in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p
	{margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
address
	{mso-style-link:"HTML Address Char";
	margin:0in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-style:italic;}
pre
	{mso-style-link:"HTML Preformatted Char";
	margin:0in;
	line-height:13.0pt;
	font-size:10.0pt;
	font-family:"Courier New";}
p.MsoCommentSubject, li.MsoCommentSubject, div.MsoCommentSubject
	{mso-style-link:"Comment Subject Char";
	margin:0in;
	line-height:13.0pt;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.MsoAcetate, li.MsoAcetate, div.MsoAcetate
	{mso-style-link:"Balloon Text Char";
	margin:0in;
	line-height:13.0pt;
	font-size:9.0pt;
	font-family:"Times New Roman",serif;}
p.MsoNoSpacing, li.MsoNoSpacing, div.MsoNoSpacing
	{margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoRMPane, li.MsoRMPane, div.MsoRMPane
	{margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListParagraph, li.MsoListParagraph, div.MsoListParagraph
	{margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:.5in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListParagraphCxSpFirst, li.MsoListParagraphCxSpFirst, div.MsoListParagraphCxSpFirst
	{margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListParagraphCxSpMiddle, li.MsoListParagraphCxSpMiddle, div.MsoListParagraphCxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListParagraphCxSpLast, li.MsoListParagraphCxSpLast, div.MsoListParagraphCxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:.5in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoQuote, li.MsoQuote, div.MsoQuote
	{mso-style-link:"Quote Char";
	margin-top:10.0pt;
	margin-right:.6in;
	margin-bottom:8.0pt;
	margin-left:.6in;
	text-align:center;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:#404040;
	font-style:italic;}
p.MsoIntenseQuote, li.MsoIntenseQuote, div.MsoIntenseQuote
	{mso-style-link:"Intense Quote Char";
	margin-top:.25in;
	margin-right:.6in;
	margin-bottom:.25in;
	margin-left:.6in;
	text-align:center;
	line-height:13.0pt;
	border:none;
	padding:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:#5B9BD5;
	font-style:italic;}
p.MsoBibliography, li.MsoBibliography, div.MsoBibliography
	{margin:0in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoTocHeading, li.MsoTocHeading, div.MsoTocHeading
	{margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	line-height:13.0pt;
	page-break-after:avoid;
	font-size:16.0pt;
	font-family:"Calibri Light",sans-serif;
	font-weight:bold;}
span.Heading1Char
	{mso-style-name:"Heading 1 Char";
	mso-style-link:"Heading 1";
	font-family:"Times New Roman",serif;
	text-transform:uppercase;
	font-weight:bold;}
span.Heading2Char
	{mso-style-name:"Heading 2 Char";
	mso-style-link:"Heading 2";
	font-family:"Times New Roman",serif;
	font-weight:bold;}
span.Heading3Char
	{mso-style-name:"Heading 3 Char";
	mso-style-link:"Heading 3";
	font-family:"Times New Roman",serif;
	font-weight:bold;}
span.Heading4Char
	{mso-style-name:"Heading 4 Char";
	mso-style-link:"Heading 4";
	font-family:"Times New Roman",serif;
	font-weight:bold;}
span.Heading5Char
	{mso-style-name:"Heading 5 Char";
	mso-style-link:"Heading 5";
	font-family:"Times New Roman",serif;
	font-weight:bold;}
span.Heading6Char
	{mso-style-name:"Heading 6 Char";
	mso-style-link:"Heading 6";
	font-family:"Times New Roman",serif;
	font-weight:bold;}
span.Heading7Char
	{mso-style-name:"Heading 7 Char";
	mso-style-link:"Heading 7";
	font-family:"Times New Roman",serif;}
span.Heading8Char
	{mso-style-name:"Heading 8 Char";
	mso-style-link:"Heading 8";
	font-family:"Times New Roman",serif;}
span.FooterChar
	{mso-style-name:"Footer Char";
	mso-style-link:Footer;
	font-family:"Arial",sans-serif;}
span.HeaderChar
	{mso-style-name:"Header Char";
	mso-style-link:Header;
	font-family:"Arial",sans-serif;}
p.MemoHeaderStyle, li.MemoHeaderStyle, div.MemoHeaderStyle
	{mso-style-name:MemoHeaderStyle;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:70.9pt;
	text-align:justify;
	text-justify:inter-ideograph;
	font-size:11.0pt;
	font-family:"Arial",sans-serif;
	font-variant:small-caps;
	font-weight:bold;}
span.BodyTextChar
	{mso-style-name:"Body Text Char";
	mso-style-link:"Body Text";}
span.CommentTextChar
	{mso-style-name:"Comment Text Char\,Car17 Char\,Car17 Car Char\,Car17 Car Car Char\,Char13 Char\,Char13 Car Char\,Char13 Car Car Char";
	mso-style-link:"Comment Text\,Car17\,Car17 Car\,Car17 Car Car\,Char13\,Char13 Car\,Char13 Car Car";
	font-family:"Times New Roman",serif;}
p.EMEAEnBodyText, li.EMEAEnBodyText, div.EMEAEnBodyText
	{mso-style-name:"EMEA En Body Text";
	margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:0in;
	text-align:justify;
	text-justify:inter-ideograph;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
span.BalloonTextChar
	{mso-style-name:"Balloon Text Char";
	mso-style-link:"Balloon Text";
	font-family:SimSun;}
p.BodytextAgency, li.BodytextAgency, div.BodytextAgency
	{mso-style-name:"Body text \(Agency\)";
	mso-style-link:"Body text \(Agency\) Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:7.0pt;
	margin-left:0in;
	line-height:14.0pt;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;}
span.BodytextAgencyChar
	{mso-style-name:"Body text \(Agency\) Char";
	mso-style-link:"Body text \(Agency\)";
	font-family:"Verdana",sans-serif;}
p.DraftingNotesAgency, li.DraftingNotesAgency, div.DraftingNotesAgency
	{mso-style-name:"Drafting Notes \(Agency\)";
	mso-style-link:"Drafting Notes \(Agency\) Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:7.0pt;
	margin-left:0in;
	line-height:14.0pt;
	font-size:9.0pt;
	font-family:"Courier New";
	color:#339966;
	font-style:italic;}
span.DraftingNotesAgencyChar
	{mso-style-name:"Drafting Notes \(Agency\) Char";
	mso-style-link:"Drafting Notes \(Agency\)";
	font-family:"Courier New";
	color:#339966;
	font-style:italic;}
p.NormalAgency, li.NormalAgency, div.NormalAgency
	{mso-style-name:"Normal \(Agency\)";
	mso-style-link:"Normal \(Agency\) Char";
	margin:0in;
	font-size:11.0pt;
	font-family:"Verdana",sans-serif;}
p.TableheadingrowsAgency, li.TableheadingrowsAgency, div.TableheadingrowsAgency
	{mso-style-name:"Table heading rows \(Agency\)";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:7.0pt;
	margin-left:0in;
	line-height:14.0pt;
	page-break-after:avoid;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;
	font-weight:bold;}
p.TabletextrowsAgency, li.TabletextrowsAgency, div.TabletextrowsAgency
	{mso-style-name:"Table text rows \(Agency\)";
	margin:0in;
	line-height:14.0pt;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;}
span.NormalAgencyChar
	{mso-style-name:"Normal \(Agency\) Char";
	mso-style-link:"Normal \(Agency\)";
	font-family:"Verdana",sans-serif;}
span.CommentSubjectChar
	{mso-style-name:"Comment Subject Char";
	mso-style-link:"Comment Subject";
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.Revisjon1, li.Revisjon1, div.Revisjon1
	{mso-style-name:Revisjon1;
	margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.Default, li.Default, div.Default
	{mso-style-name:Default;
	margin:0in;
	text-autospace:none;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.Table, li.Table, div.Table
	{mso-style-name:Table;
	margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:141.8pt;
	text-indent:-56.7pt;
	page-break-after:avoid;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.TWNormal, li.TWNormal, div.TWNormal
	{mso-style-name:"TW Normal";
	margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.Listeavsnitt1, li.Listeavsnitt1, div.Listeavsnitt1
	{mso-style-name:Listeavsnitt1;
	margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:.5in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.Listeavsnitt1CxSpFirst, li.Listeavsnitt1CxSpFirst, div.Listeavsnitt1CxSpFirst
	{mso-style-name:Listeavsnitt1CxSpFirst;
	margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.Listeavsnitt1CxSpMiddle, li.Listeavsnitt1CxSpMiddle, div.Listeavsnitt1CxSpMiddle
	{mso-style-name:Listeavsnitt1CxSpMiddle;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.Listeavsnitt1CxSpLast, li.Listeavsnitt1CxSpLast, div.Listeavsnitt1CxSpLast
	{mso-style-name:Listeavsnitt1CxSpLast;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:.5in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
span.FootnoteTextChar
	{mso-style-name:"Footnote Text Char";
	mso-style-link:"Footnote Text";
	font-family:"Times New Roman",serif;}
p.TableFootnote, li.TableFootnote, div.TableFootnote
	{mso-style-name:"Table Footnote";
	margin:0in;
	font-size:8.0pt;
	font-family:"Arial",sans-serif;}
p.TableText, li.TableText, div.TableText
	{mso-style-name:"Table Text";
	mso-style-link:"Table Text Char";
	margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:0in;
	font-size:11.0pt;
	font-family:"Verdana",sans-serif;}
p.TableTitle, li.TableTitle, div.TableTitle
	{mso-style-name:"Table Title";
	mso-style-link:"Table Title Char";
	margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:0in;
	text-align:justify;
	text-justify:inter-ideograph;
	page-break-after:avoid;
	font-size:9.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
span.TableTextChar
	{mso-style-name:"Table Text Char";
	mso-style-link:"Table Text";
	font-family:"Verdana",sans-serif;}
span.TableTitleChar
	{mso-style-name:"Table Title Char";
	mso-style-link:"Table Title";
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.Body, li.Body, div.Body
	{mso-style-name:Body;
	mso-style-link:"Body Car";
	margin-top:3.0pt;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	text-align:justify;
	text-justify:inter-ideograph;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
span.BodyCar
	{mso-style-name:"Body Car";
	mso-style-link:Body;
	font-family:"Times New Roman",serif;}
p.QRDBookmark, li.QRDBookmark, div.QRDBookmark
	{mso-style-name:"QRD Bookmark";
	margin:0in;
	text-align:center;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	text-transform:uppercase;
	font-weight:bold;}
p.BodytextEMA, li.BodytextEMA, div.BodytextEMA
	{mso-style-name:"Body text \(EMA\)";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:7.0pt;
	margin-left:0in;
	line-height:14.0pt;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;}
p.QRDBookmark2, li.QRDBookmark2, div.QRDBookmark2
	{mso-style-name:"QRD Bookmark2";
	margin:0in;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
span.BodyText2Char
	{mso-style-name:"Body Text 2 Char";
	mso-style-link:"Body Text 2";}
span.BodyText3Char
	{mso-style-name:"Body Text 3 Char";
	mso-style-link:"Body Text 3";}
span.BodyTextFirstIndentChar
	{mso-style-name:"Body Text First Indent Char";
	mso-style-link:"Body Text First Indent";}
span.BodyTextIndentChar
	{mso-style-name:"Body Text Indent Char";
	mso-style-link:"Body Text Indent";}
span.BodyTextFirstIndent2Char
	{mso-style-name:"Body Text First Indent 2 Char";
	mso-style-link:"Body Text First Indent 2";}
span.BodyTextIndent2Char
	{mso-style-name:"Body Text Indent 2 Char";
	mso-style-link:"Body Text Indent 2";}
span.BodyTextIndent3Char
	{mso-style-name:"Body Text Indent 3 Char";
	mso-style-link:"Body Text Indent 3";}
span.ClosingChar
	{mso-style-name:"Closing Char";
	mso-style-link:Closing;}
span.DateChar
	{mso-style-name:"Date Char";
	mso-style-link:Date;}
span.DocumentMapChar
	{mso-style-name:"Document Map Char";
	mso-style-link:"Document Map";
	font-family:"Segoe UI",sans-serif;}
span.E-mailSignatureChar
	{mso-style-name:"E-mail Signature Char";
	mso-style-link:"E-mail Signature";}
span.EndnoteTextChar
	{mso-style-name:"Endnote Text Char";
	mso-style-link:"Endnote Text";}
span.Heading9Char
	{mso-style-name:"Heading 9 Char";
	mso-style-link:"Heading 9";
	font-family:"Calibri Light",sans-serif;}
span.HTMLAddressChar
	{mso-style-name:"HTML Address Char";
	mso-style-link:"HTML Address";
	font-style:italic;}
span.HTMLPreformattedChar
	{mso-style-name:"HTML Preformatted Char";
	mso-style-link:"HTML Preformatted";
	font-family:"Courier New";}
span.IntenseQuoteChar
	{mso-style-name:"Intense Quote Char";
	mso-style-link:"Intense Quote";
	color:#5B9BD5;
	font-style:italic;}
span.MacroTextChar
	{mso-style-name:"Macro Text Char";
	mso-style-link:"Macro Text";
	font-family:"Courier New";}
span.MessageHeaderChar
	{mso-style-name:"Message Header Char";
	mso-style-link:"Message Header";
	font-family:"Calibri Light",sans-serif;
	background:#CCCCCC;}
span.NoteHeadingChar
	{mso-style-name:"Note Heading Char";
	mso-style-link:"Note Heading";}
span.PlainTextChar
	{mso-style-name:"Plain Text Char";
	mso-style-link:"Plain Text";
	font-family:"Courier New";}
span.QuoteChar
	{mso-style-name:"Quote Char";
	mso-style-link:Quote;
	color:#404040;
	font-style:italic;}
span.SalutationChar
	{mso-style-name:"Salutation Char";
	mso-style-link:Salutation;}
span.SignatureChar
	{mso-style-name:"Signature Char";
	mso-style-link:Signature;}
span.SubtitleChar
	{mso-style-name:"Subtitle Char";
	mso-style-link:Subtitle;
	font-family:"Calibri Light",sans-serif;}
span.TitleChar
	{mso-style-name:"Title Char";
	mso-style-link:Title;
	font-family:"Calibri Light",sans-serif;
	font-weight:bold;}
p.No-numheading3Agency, li.No-numheading3Agency, div.No-numheading3Agency
	{mso-style-name:"No-num heading 3 \(Agency\)";
	mso-style-link:"No-num heading 3 \(Agency\) Char";
	margin-top:14.0pt;
	margin-right:0in;
	margin-bottom:11.0pt;
	margin-left:0in;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Verdana",sans-serif;
	font-weight:bold;}
span.No-numheading3AgencyChar
	{mso-style-name:"No-num heading 3 \(Agency\) Char";
	mso-style-link:"No-num heading 3 \(Agency\)";
	font-family:"Verdana",sans-serif;
	font-weight:bold;}
 /* Page Definitions */
 @page WordSection1
	{size:595.35pt 842.0pt;
	margin:56.7pt 70.9pt 56.7pt 70.9pt;}
div.WordSection1
	{page:WordSection1;}
 /* List Definitions */
 ol
	{margin-bottom:0in;}
ul
	{margin-bottom:0in;}
-->
</style>"/>
          </Binary>
        </contained>
        <extension url="http://ema.europa.eu/fhir/extension/dummyValidationReference">
          <valueReference>
            <reference value="#stylesheet0"/>
          </valueReference>
        </extension>
        <status value="final"/>
        <type>
          <coding>
            <system value="http://spor.ema.europa.eu/v1/lists/100000155531"/>
            <code value="100000155532"/>
            <display value="PREPARATOMTALE"/>
          </coding>
        </type>
        <subject>
          <reference value="[]"/>
        </subject>
        <date value="2021-02-01"/>
        <author>
          <identifier>
            <system value="[]"/>
          </identifier>
        </author>
        <title value="Acme Product"/>
        <relatesTo>
          <code value="appends"/>
          <targetReference>
            <reference value="${document[n].relatesTo}"/>
          </targetReference>
        </relatesTo>
        <section id="dd73476d-11a5-4ca6-8cd7-398851990760">
          <title value="PREPARATOMTALE"/>
          <code>
            <coding>
              <system value="http://spor.ema.europa.eu/v1/example-sections"/>
              <code value="1"/>
              <display value="PREPARATOMTALE"/>
            </coding>
          </code>
          <text>
            <status value="additional"/><div xmlns="http://www.w3.org/1999/xhtml">
                            <span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;,serif;  color:green" lang="NO-BOK">
                                <br clear="all" style="page-break-before:always"/>
                            </span>
                            <br clear="all" style="page-break-before:always"/>
                        </div>
          </text>
          <section id="4af9071e-08ed-49e1-8e94-f5751e5287ed">
            <title value="1.       LEGEMIDLETS NAVN"/>
            <code>
              <coding>
                <system value="http://spor.ema.europa.eu/v1/example-sections"/>
                <code value="3"/>
                <display value="1. LEGEMIDLETS NAVN"/>
              </coding>
            </code>
            <text>
              <status value="additional"/><div xmlns="http://www.w3.org/1999/xhtml">
                                <p style="line-height:normal;page-break-after:avoid" class="MsoNormal"/>
                                <p style="line-height:normal;page-break-after:avoid" class="MsoNormal">
                                    <span lang="NO-BOK">Acme Product 30 mg enterotabletter</span>
                                </p>
                                <p style="line-height:normal" class="MsoNormal">
                                    <span lang="NO-BOK">Acme Product 120 mg enterotabletter</span>
                                </p>
                                <p style="line-height:normal" class="MsoNormal"/>
                                <p style="line-height:normal" class="MsoNormal"/>
                            </div>
            </text>
          </section>
          <section id="7f61983d-3508-46c6-96f7-f069c3c544a3">
            <title value="2.       KVALITATIV OG KVANTITATIV SAMMENSETNING"/>
            <code>
              <coding>
                <system value="http://spor.ema.europa.eu/v1/example-sections"/>
                <code value="4"/>
                <display value="2. KVALITATIV OG KVANTITATIV SAMMENSETNING"/>
              </coding>
            </code>
            <text>
              <status value="additional"/><div xmlns="http://www.w3.org/1999/xhtml">
                                <p style="line-height:normal;page-break-after:avoid" class="MsoNormal"/>
                                <p style="line-height:normal;page-break-after:avoid" class="MsoNormal">
                                    <u>
                                        <span lang="NO-BOK">Acme Product 30 mg</span>
                                    </u>
                                </p>
                                <p style="line-height:normal;page-break-after:avoid" class="MsoNormal">
                                    <span lang="NO-BOK">Hver enterotablett inneholder 30 mg dimetylfumarat.</span>
                                </p>
                                <p style="line-height:normal;page-break-after:avoid" class="MsoNormal">
                                    <u>
                                        <span lang="NO-BOK">Acme Product 120 mg</span>
                                    </u>
                                </p>
                                <p style="line-height:normal;page-break-after:avoid" class="MsoNormal">
                                    <span lang="NO-BOK">Hver enterotablett inneholder 120 mg dimetylfumarat.</span>
                                </p>
                                <p style="line-height:normal" class="MsoNormal"/>
                            </div>
            </text>
            <section id="07a757b3-2ee0-4b50-8501-d009425d000f">
              <title value="Hjelpestoff med kjent effekt"/>
              <code>
                <coding>
                  <system value="http://spor.ema.europa.eu/v1/example-sections"/>
                  <code value="7"/>
                  <display value="Hjelpestoff(er) med kjent effekt"/>
                </coding>
              </code>
              <text>
                <status value="additional"/><div xmlns="http://www.w3.org/1999/xhtml">
                                    <p style="line-height:normal;page-break-after:avoid" class="MsoNormal">
                                        <u>
                                            <span lang="NO-BOK">Acme Product 30 mg</span>
                                        </u>
                                    </p>
                                    <p style="line-height:normal;page-break-after:avoid" class="MsoNormal">
                                        <span lang="NO-BOK">Hver enterotablett inneholder 34,2 mg laktose (som monohydrat).</span>
                                    </p>
                                    <p style="line-height:normal;page-break-after:avoid" class="MsoNormal">
                                        <u>
                                            <span lang="NO-BOK">Acme Product 120 mg</span>
                                        </u>
                                    </p>
                                    <p style="line-height:normal;page-break-after:avoid" class="MsoNormal">
                                        <span lang="NO-BOK">Hver enterotablett inneholder 136,8 mg laktose (som monohydrat).</span>
                                    </p>
                                    <p style="line-height:normal" class="MsoNormal"/>
                                    <p style="line-height:normal" class="MsoNormal">
                                        <span lang="NO-BOK">For fullstendig liste over hjelpestoffer, se pkt. 6.1.</span>
                                    </p>
                                    <p style="line-height:normal" class="MsoNormal"/>
                                    <p style="line-height:normal" class="MsoNormal"/>
                                </div>
              </text>
            </section>
          </section>
          <section id="4a2a8397-7ff0-4b3b-a3fd-25396bfbbf83">
            <title value="3.       LEGEMIDDELFORM"/>
            <code>
              <coding>
                <system value="http://spor.ema.europa.eu/v1/example-sections"/>
                <code value="8"/>
                <display value="3. LEGEMIDDELFORM"/>
              </coding>
            </code>
            <text>
              <status value="additional"/><div xmlns="http://www.w3.org/1999/xhtml">
                                <p style="line-height:normal;page-break-after:avoid" class="MsoNormal"/>
                                <p style="line-height:normal;page-break-after:avoid" class="MsoNormal">
                                    <span lang="NO-BOK">Enterotablett.</span>
                                </p>
                                <p style="line-height:normal;page-break-after:avoid" class="MsoNormal">
                                    <u>
                                        <span lang="NO-BOK">Acme Product 30 mg</span>
                                    </u>
                                </p>
                                <p style="line-height:normal;page-break-after:avoid" class="MsoNormal">
                                    <span lang="NO-BOK">Hvit, filmdrasjert, rund, bikonveks tablett med en diameter p omtrent 6,8 mm. </span>
                                </p>
                                <p style="line-height:normal;page-break-after:avoid" class="MsoNormal">
                                    <u>
                                        <span lang="NO-BOK">Acme Product 120 mg</span>
                                    </u>
                                </p>
                                <p style="line-height:normal;page-break-after:avoid" class="MsoNormal">
                                    <span lang="NO-BOK">Bl, filmdrasjert, rund, bikonveks tablett med en diameter p omtrent 11,6 mm. </span>
                                </p>
                                <p style="line-height:normal" class="MsoNormal"/>
                                <p style="line-height:normal" class="MsoNormal"/>
                            </div>
            </text>
          </section>
          <section id="f2d48864-01c6-415a-9841-867b35715dff">
            <title value="4.       KLINISKE OPPLYSNINGER"/>
            <code>
              <coding>
                <system value="http://spor.ema.europa.eu/v1/example-sections"/>
                <code value="9"/>
                <display value="4. KLINISKE OPPLYSNINGER"/>
              </coding>
            </code>
            <text>
              <status value="additional"/><div xmlns="http://www.w3.org/1999/xhtml">
                                <p style="margin-left:28.35pt;text-indent:-28.35pt;line-height:  normal;page-break-after:avoid" class="MsoNormal"/>
                            </div>
            </text>
            <section id="dc99f499-3c44-4337-aa3d-26e3d9c0d0bc">
              <title value="4.1     Indikasjoner"/>
              <code>
                <coding>
                  <system value="http://spor.ema.europa.eu/v1/example-sections"/>
                  <code value="10"/>
                  <display value="4.1 Indikasjon(er)"/>
                </coding>
              </code>
              <text>
                <status value="additional"/><div xmlns="http://www.w3.org/1999/xhtml">
                                    <p style="line-height:normal;page-break-after:avoid" class="MsoNormal"/>
                                    <p style="line-height:normal;page-break-after:avoid" class="MsoNormal">
                                        <span lang="NO-BOK">Acme Product er indisert til behandling av moderat til alvorlig plakkpsoriasis hos voksne som har behov for systemisk medisinsk behandling. </span>
                                    </p>
                                    <p style="line-height:normal" class="MsoNormal"/>
                                </div>
              </text>
            </section>
            <section id="fd5ee14d-0a47-4a6e-89a3-a22fc6e1a614">
              <title value="4.2     Dosering og administrasjonsm&#xE5;te"/>
              <code>
                <coding>
                  <system value="http://spor.ema.europa.eu/v1/example-sections"/>
                  <code value="11"/>
                  <display value="4.2 Dosering og administrasjonsm&#xE5;te"/>
                </coding>
              </code>
              <text>
                <status value="additional"/><div xmlns="http://www.w3.org/1999/xhtml">
                                    <p style="margin-left:28.35pt;text-indent:-28.35pt;line-height:  normal;page-break-after:avoid" class="MsoNormal"/>
                                    <p style="text-indent:-1.35pt;line-height:normal;page-break-after:  avoid" class="MsoNormal">
                                        <span lang="NO-BOK">Acme Product er beregnet til bruk under veiledning og tilsyn av en lege som har erfaring innen diagnostisering og behandling av psoriasis.</span>
                                    </p>
                                    <p style="line-height:normal;page-break-after:avoid" class="MsoNormal">
                                        <u>
                                            <span lang="NO-BOK"/>
                                        </u>
                                    </p>
                                </div>
              </text>
              <section id="80703ee9-c748-429d-bcb8-c3d84f8ebc3c">
                <title value="Dosering"/>
                <code>
                  <coding>
                    <system value="http://spor.ema.europa.eu/v1/example-sections"/>
                    <code value="12"/>
                    <display value="Dosering"/>
                  </coding>
                </code>
                <text>
                  <status value="additional"/><div xmlns="http://www.w3.org/1999/xhtml">
                                        <p style="line-height:normal;page-break-after:avoid" class="MsoNormal">
                                            <span lang="NO-BOK">For  bedre toleransen anbefales det  begynne behandlingen med en lav startdose med gradvis kning. I den frste uken skal Acme Product 30 mg tas n gang daglig (1 tablett om kvelden). I den andre uken skal Acme Product 30 mg tas to ganger daglig (1 tablett om morgenen og 1 om kvelden). I den tredje uken skal Acme Product 30 mg tas tre ganger daglig (1 tablett om morgenen, 1 midt p dagen, og 1 om kvelden). Fra den fjerde uken skal behandlingen endres til bare 1 Acme Product 120 mg tablett om kvelden. Denne dosen kes deretter med 1 Acme Product 120 mg tablett per uke p ulike tider av dgnet i de neste 5 ukene, som vist i tabellen nedenfor. Maksimal tillatt daglig dose er 720 mg (3 x 2 tabletter Acme Product 120 mg).</span>
                                        </p>
                                        <p style="line-height:normal" class="MsoNormal"/>
                                        <table border="0" cellpadding="0" cellspacing="0" width="100%" style="width:100.0%;border-collapse:collapse" class="MsoNormalTable">
                                            <tr>
                                                <td width="10%" style="width:10.42%;border:solid windowtext 1.0pt;    border-bottom:none;padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top">
                                                    <p style="line-height:normal;page-break-after:avoid" class="MsoNormal">
                                                        <b>
                                                            <span lang="NO-BOK">Uke</span>
                                                        </b>
                                                    </p>
                                                </td>
                                                <td colspan="3" width="62%" style="width:62.5%;border:solid windowtext 1.0pt;    border-left:none;padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top">
                                                    <p style="text-align:center;line-height:normal;    page-break-after:avoid" align="center" class="MsoNormal">
                                                        <b>
                                                            <span lang="NO-BOK">Antall tabletter</span>
                                                        </b>
                                                    </p>
                                                </td>
                                                <td width="27%" style="width:27.08%;border-top:solid windowtext 1.0pt;    border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top">
                                                    <p style="text-align:center;line-height:normal;    page-break-after:avoid" align="center" class="MsoNormal">
                                                        <b>
                                                            <span lang="NO-BOK">Total daglig dose (mg)</span>
                                                        </b>
                                                    </p>
                                                </td>
                                            </tr>
                                            <tr>
                                                <td width="10%" style="width:10.42%;border:solid windowtext 1.0pt;    border-top:none;padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top">
                                                    <p style="line-height:normal;page-break-after:avoid" class="MsoNormal"/>
                                                </td>
                                                <td width="20%" style="width:20.84%;border-top:none;border-left:    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top">
                                                    <p style="text-align:center;line-height:normal;    page-break-after:avoid" align="center" class="MsoNormal">
                                                        <b>
                                                            <span lang="NO-BOK">Morgen</span>
                                                        </b>
                                                    </p>
                                                </td>
                                                <td width="20%" style="width:20.84%;border:solid windowtext 1.0pt;    border-left:none;padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top">
                                                    <p style="text-align:center;line-height:normal;    page-break-after:avoid" align="center" class="MsoNormal">
                                                        <b>
                                                            <span lang="NO-BOK">Midt p dagen</span>
                                                        </b>
                                                    </p>
                                                </td>
                                                <td width="20%" style="width:20.84%;border:solid windowtext 1.0pt;    border-left:none;padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top">
                                                    <p style="text-align:center;line-height:normal;    page-break-after:avoid" align="center" class="MsoNormal">
                                                        <b>
                                                            <span lang="NO-BOK">Kveld</span>
                                                        </b>
                                                    </p>
                                                </td>
                                                <td width="27%" style="width:27.08%;border-top:none;border-left:    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top">
                                                    <p style="text-align:center;line-height:normal;    page-break-after:avoid" align="center" class="MsoNormal">
                                                        <b>
                                                            <span lang="NO-BOK">med dimetylfumarat </span>
                                                        </b>
                                                    </p>
                                                </td>
                                            </tr>
                                            <tr>
                                                <td colspan="4" width="72%" style="width:72.92%;border-top:none;    border-left:solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;    border-right:none;padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top">
                                                    <p style="text-align:center;line-height:normal;    page-break-after:avoid" align="center" class="MsoNormal">
                                                        <b>
                                                            <span lang="NO-BOK">Acme Product 30 mg</span>
                                                        </b>
                                                    </p>
                                                </td>
                                                <td width="27%" style="width:27.08%;border-top:none;border-left:    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top">
                                                    <p style="text-align:center;line-height:normal;    page-break-after:avoid" align="center" class="MsoNormal"/>
                                                </td>
                                            </tr>
                                            <tr>
                                                <td width="10%" style="width:10.42%;border-top:none;border-left:solid windowtext 1.0pt;    border-bottom:none;border-right:solid windowtext 1.0pt;padding:1.4pt 5.4pt 1.4pt 5.4pt">
                                                    <p style="line-height:normal;page-break-after:avoid" class="MsoNormal">
                                                        <span lang="NO-BOK">1</span>
                                                    </p>
                                                </td>
                                                <td width="20%" style="width:20.84%;border:none;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt">
                                                    <p style="text-align:center;line-height:normal;    page-break-after:avoid" align="center" class="MsoNormal">
                                                        <span lang="NO-BOK">0</span>
                                                    </p>
                                                </td>
                                                <td width="20%" style="width:20.84%;border:none;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt">
                                                    <p style="text-align:center;line-height:normal;    page-break-after:avoid" align="center" class="MsoNormal">
                                                        <span lang="NO-BOK">0</span>
                                                    </p>
                                                </td>
                                                <td width="20%" style="width:20.84%;border:none;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt">
                                                    <p style="text-align:center;line-height:normal;    page-break-after:avoid" align="center" class="MsoNormal">
                                                        <span lang="NO-BOK">1</span>
                                                    </p>
                                                </td>
                                                <td width="27%" style="width:27.08%;border:none;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt">
                                                    <p style="text-align:center;line-height:normal;    page-break-after:avoid" align="center" class="MsoNormal">
                                                        <span lang="NO-BOK">30</span>
                                                    </p>
                                                </td>
                                            </tr>
                                            <tr>
                                                <td width="10%" style="width:10.42%;border-top:none;border-left:solid windowtext 1.0pt;    border-bottom:none;border-right:solid windowtext 1.0pt;padding:1.4pt 5.4pt 1.4pt 5.4pt">
                                                    <p style="line-height:normal;page-break-after:avoid" class="MsoNormal">
                                                        <span lang="NO-BOK">2</span>
                                                    </p>
                                                </td>
                                                <td width="20%" style="width:20.84%;border:none;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt">
                                                    <p style="text-align:center;line-height:normal;    page-break-after:avoid" align="center" class="MsoNormal">
                                                        <span lang="NO-BOK">1</span>
                                                    </p>
                                                </td>
                                                <td width="20%" style="width:20.84%;border:none;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt">
                                                    <p style="text-align:center;line-height:normal;    page-break-after:avoid" align="center" class="MsoNormal">
                                                        <span lang="NO-BOK">0</span>
                                                    </p>
                                                </td>
                                                <td width="20%" style="width:20.84%;border:none;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt">
                                                    <p style="text-align:center;line-height:normal;    page-break-after:avoid" align="center" class="MsoNormal">
                                                        <span lang="NO-BOK">1</span>
                                                    </p>
                                                </td>
                                                <td width="27%" style="width:27.08%;border:none;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt">
                                                    <p style="text-align:center;line-height:normal;    page-break-after:avoid" align="center" class="MsoNormal">
                                                        <span lang="NO-BOK">60</span>
                                                    </p>
                                                </td>
                                            </tr>
                                            <tr>
                                                <td width="10%" style="width:10.42%;border:solid windowtext 1.0pt;border-top:    none;padding:1.4pt 5.4pt 1.4pt 5.4pt">
                                                    <p style="line-height:normal;page-break-after:avoid" class="MsoNormal">
                                                        <span lang="NO-BOK">3</span>
                                                    </p>
                                                </td>
                                                <td width="20%" style="width:20.84%;border-top:none;border-left:none;    border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt">
                                                    <p style="text-align:center;line-height:normal;    page-break-after:avoid" align="center" class="MsoNormal">
                                                        <span lang="NO-BOK">1</span>
                                                    </p>
                                                </td>
                                                <td width="20%" style="width:20.84%;border-top:none;border-left:none;    border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt">
                                                    <p style="text-align:center;line-height:normal;    page-break-after:avoid" align="center" class="MsoNormal">
                                                        <span lang="NO-BOK">1</span>
                                                    </p>
                                                </td>
                                                <td width="20%" style="width:20.84%;border-top:none;border-left:none;    border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt">
                                                    <p style="text-align:center;line-height:normal;    page-break-after:avoid" align="center" class="MsoNormal">
                                                        <span lang="NO-BOK">1</span>
                                                    </p>
                                                </td>
                                                <td width="27%" style="width:27.08%;border-top:none;border-left:none;    border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt">
                                                    <p style="text-align:center;line-height:normal;    page-break-after:avoid" align="center" class="MsoNormal">
                                                        <span lang="NO-BOK">90</span>
                                                    </p>
                                                </td>
                                            </tr>
                                            <tr>
                                                <td colspan="4" width="72%" style="width:72.92%;border-top:none;border-left:    solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:    none;padding:1.4pt 5.4pt 1.4pt 5.4pt">
                                                    <p style="text-align:center;line-height:normal;    page-break-after:avoid" align="center" class="MsoNormal">
                                                        <b>
                                                            <span lang="NO-BOK">Acme Product 120 mg</span>
                                                        </b>
                                                    </p>
                                                </td>
                                                <td width="27%" style="width:27.08%;border-top:none;border-left:none;    border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt">
                                                    <p style="text-align:center;line-height:normal;    page-break-after:avoid" align="center" class="MsoNormal"/>
                                                </td>
                                            </tr>
                                            <tr style="height:11.55pt">
                                                <td width="10%" style="width:10.42%;border-top:none;border-left:solid windowtext 1.0pt;    border-bottom:none;border-right:solid windowtext 1.0pt;padding:1.4pt 5.4pt 1.4pt 5.4pt;    height:11.55pt">
                                                    <p style="line-height:normal;page-break-after:avoid" class="MsoNormal">
                                                        <span lang="NO-BOK">4</span>
                                                    </p>
                                                </td>
                                                <td width="20%" style="width:20.84%;border:none;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt;height:11.55pt">
                                                    <p style="text-align:center;line-height:normal;    page-break-after:avoid" align="center" class="MsoNormal">
                                                        <span lang="NO-BOK">0</span>
                                                    </p>
                                                </td>
                                                <td width="20%" style="width:20.84%;border:none;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt;height:11.55pt">
                                                    <p style="text-align:center;line-height:normal;    page-break-after:avoid" align="center" class="MsoNormal">
                                                        <span lang="NO-BOK">0</span>
                                                    </p>
                                                </td>
                                                <td width="20%" style="width:20.84%;border:none;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt;height:11.55pt">
                                                    <p style="text-align:center;line-height:normal;    page-break-after:avoid" align="center" class="MsoNormal">
                                                        <span lang="NO-BOK">1</span>
                                                    </p>
                                                </td>
                                                <td width="27%" style="width:27.08%;border:none;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt;height:11.55pt">
                                                    <p style="text-align:center;line-height:normal;    page-break-after:avoid" align="center" class="MsoNormal">
                                                        <span lang="NO-BOK">120</span>
                                                    </p>
                                                </td>
                                            </tr>
                                            <tr style="height:12.65pt">
                                                <td width="10%" style="width:10.42%;border-top:none;border-left:solid windowtext 1.0pt;    border-bottom:none;border-right:solid windowtext 1.0pt;padding:1.4pt 5.4pt 1.4pt 5.4pt;    height:12.65pt">
                                                    <p style="line-height:normal;page-break-after:avoid" class="MsoNormal">
                                                        <span lang="NO-BOK">5</span>
                                                    </p>
                                                </td>
                                                <td width="20%" style="width:20.84%;border:none;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt;height:12.65pt">
                                                    <p style="text-align:center;line-height:normal;    page-break-after:avoid" align="center" class="MsoNormal">
                                                        <span lang="NO-BOK">1</span>
                                                    </p>
                                                </td>
                                                <td width="20%" style="width:20.84%;border:none;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt;height:12.65pt">
                                                    <p style="text-align:center;line-height:normal;    page-break-after:avoid" align="center" class="MsoNormal">
                                                        <span lang="NO-BOK">0</span>
                                                    </p>
                                                </td>
                                                <td width="20%" style="width:20.84%;border:none;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt;height:12.65pt">
                                                    <p style="text-align:center;line-height:normal;    page-break-after:avoid" align="center" class="MsoNormal">
                                                        <span lang="NO-BOK">1</span>
                                                    </p>
                                                </td>
                                                <td width="27%" style="width:27.08%;border:none;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt;height:12.65pt">
                                                    <p style="text-align:center;line-height:normal;    page-break-after:avoid" align="center" class="MsoNormal">
                                                        <span lang="NO-BOK">240</span>
                                                    </p>
                                                </td>
                                            </tr>
                                            <tr style="height:16.15pt">
                                                <td width="10%" style="width:10.42%;border-top:none;border-left:solid windowtext 1.0pt;    border-bottom:none;border-right:solid windowtext 1.0pt;padding:1.4pt 5.4pt 1.4pt 5.4pt;    height:16.15pt">
                                                    <p style="line-height:normal;page-break-after:avoid" class="MsoNormal">
                                                        <span lang="NO-BOK">6</span>
                                                    </p>
                                                </td>
                                                <td width="20%" style="width:20.84%;border:none;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt;height:16.15pt">
                                                    <p style="text-align:center;line-height:normal;    page-break-after:avoid" align="center" class="MsoNormal">
                                                        <span lang="NO-BOK">1</span>
                                                    </p>
                                                </td>
                                                <td width="20%" style="width:20.84%;border:none;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt;height:16.15pt">
                                                    <p style="text-align:center;line-height:normal;    page-break-after:avoid" align="center" class="MsoNormal">
                                                        <span lang="NO-BOK">1</span>
                                                    </p>
                                                </td>
                                                <td width="20%" style="width:20.84%;border:none;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt;height:16.15pt">
                                                    <p style="text-align:center;line-height:normal;    page-break-after:avoid" align="center" class="MsoNormal">
                                                        <span lang="NO-BOK">1</span>
                                                    </p>
                                                </td>
                                                <td width="27%" style="width:27.08%;border:none;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt;height:16.15pt">
                                                    <p style="text-align:center;line-height:normal;    page-break-after:avoid" align="center" class="MsoNormal">
                                                        <span lang="NO-BOK">360</span>
                                                    </p>
                                                </td>
                                            </tr>
                                            <tr style="height:12.1pt">
                                                <td width="10%" style="width:10.42%;border-top:none;border-left:solid windowtext 1.0pt;    border-bottom:none;border-right:solid windowtext 1.0pt;padding:1.4pt 5.4pt 1.4pt 5.4pt;    height:12.1pt">
                                                    <p style="line-height:normal;page-break-after:avoid" class="MsoNormal">
                                                        <span lang="NO-BOK">7</span>
                                                    </p>
                                                </td>
                                                <td width="20%" style="width:20.84%;border:none;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt;height:12.1pt">
                                                    <p style="text-align:center;line-height:normal;    page-break-after:avoid" align="center" class="MsoNormal">
                                                        <span lang="NO-BOK">1</span>
                                                    </p>
                                                </td>
                                                <td width="20%" style="width:20.84%;border:none;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt;height:12.1pt">
                                                    <p style="text-align:center;line-height:normal;    page-break-after:avoid" align="center" class="MsoNormal">
                                                        <span lang="NO-BOK">1</span>
                                                    </p>
                                                </td>
                                                <td width="20%" style="width:20.84%;border:none;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt;height:12.1pt">
                                                    <p style="text-align:center;line-height:normal;    page-break-after:avoid" align="center" class="MsoNormal">
                                                        <span lang="NO-BOK">2</span>
                                                    </p>
                                                </td>
                                                <td width="27%" style="width:27.08%;border:none;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt;height:12.1pt">
                                                    <p style="text-align:center;line-height:normal;    page-break-after:avoid" align="center" class="MsoNormal">
                                                        <span lang="NO-BOK">480</span>
                                                    </p>
                                                </td>
                                            </tr>
                                            <tr style="height:13.25pt">
                                                <td width="10%" style="width:10.42%;border-top:none;border-left:solid windowtext 1.0pt;    border-bottom:none;border-right:solid windowtext 1.0pt;padding:1.4pt 5.4pt 1.4pt 5.4pt;    height:13.25pt">
                                                    <p style="line-height:normal;page-break-after:avoid" class="MsoNormal">
                                                        <span lang="NO-BOK">8</span>
                                                    </p>
                                                </td>
                                                <td width="20%" style="width:20.84%;border:none;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt;height:13.25pt">
                                                    <p style="text-align:center;line-height:normal;    page-break-after:avoid" align="center" class="MsoNormal">
                                                        <span lang="NO-BOK">2</span>
                                                    </p>
                                                </td>
                                                <td width="20%" style="width:20.84%;border:none;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt;height:13.25pt">
                                                    <p style="text-align:center;line-height:normal;    page-break-after:avoid" align="center" class="MsoNormal">
                                                        <span lang="NO-BOK">1</span>
                                                    </p>
                                                </td>
                                                <td width="20%" style="width:20.84%;border:none;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt;height:13.25pt">
                                                    <p style="text-align:center;line-height:normal;    page-break-after:avoid" align="center" class="MsoNormal">
                                                        <span lang="NO-BOK">2</span>
                                                    </p>
                                                </td>
                                                <td width="27%" style="width:27.08%;border:none;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt;height:13.25pt">
                                                    <p style="text-align:center;line-height:normal;    page-break-after:avoid" align="center" class="MsoNormal">
                                                        <span lang="NO-BOK">600</span>
                                                    </p>
                                                </td>
                                            </tr>
                                            <tr style="height:15.85pt">
                                                <td width="10%" style="width:10.42%;border:solid windowtext 1.0pt;border-top:    none;padding:1.4pt 5.4pt 1.4pt 5.4pt;height:15.85pt">
                                                    <p style="line-height:normal;page-break-after:avoid" class="MsoNormal">
                                                        <span lang="NO-BOK">9+</span>
                                                    </p>
                                                </td>
                                                <td width="20%" style="width:20.84%;border-top:none;border-left:none;    border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt;height:15.85pt">
                                                    <p style="text-align:center;line-height:normal;    page-break-after:avoid" align="center" class="MsoNormal">
                                                        <span lang="NO-BOK">2</span>
                                                    </p>
                                                </td>
                                                <td width="20%" style="width:20.84%;border-top:none;border-left:none;    border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt;height:15.85pt">
                                                    <p style="text-align:center;line-height:normal;    page-break-after:avoid" align="center" class="MsoNormal">
                                                        <span lang="NO-BOK">2</span>
                                                    </p>
                                                </td>
                                                <td width="20%" style="width:20.84%;border-top:none;border-left:none;    border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt;height:15.85pt">
                                                    <p style="text-align:center;line-height:normal;    page-break-after:avoid" align="center" class="MsoNormal">
                                                        <span lang="NO-BOK">2</span>
                                                    </p>
                                                </td>
                                                <td width="27%" style="width:27.08%;border-top:none;border-left:none;    border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt;height:15.85pt">
                                                    <p style="text-align:center;line-height:normal;    page-break-after:avoid" align="center" class="MsoNormal">
                                                        <span lang="NO-BOK">720</span>
                                                    </p>
                                                </td>
                                            </tr>
                                        </table>
                                        <p style="line-height:normal" class="MsoNormal"/>
                                        <p style="line-height:normal" class="MsoNormal">
                                            <span lang="NO-BOK">Hvis en bestemt dose ikke tolereres, kan den midlertidig reduseres til sist tolererte dose.</span>
                                        </p>
                                        <p style="line-height:normal" class="MsoNormal"/>
                                        <p style="line-height:normal" class="MsoNormal">
                                            <span lang="NO-BOK">Hvis behandlingseffekt observeres fr maksimaldosen er ndd, er det ikke ndvendig med ytterligere kning av dosen. Etter at en klinisk relevant forbedring av hudlesjoner er oppndd, skal det vurderes en gradvis reduksjon av den daglige dosen av Acme Product til vedlikeholdsdosen som kreves hos den enkelte person.</span>
                                        </p>
                                        <p style="line-height:normal" class="MsoNormal"/>
                                        <p style="line-height:normal" class="MsoNormal">
                                            <span lang="NO-BOK">Doseringsmodifikasjoner kan ogs vre ndvendig ved observasjon av unormale laboratorieparametre (se pkt. 4.4).</span>
                                        </p>
                                        <p style="line-height:normal" class="MsoNormal"/>
                                        <p style="line-height:normal;page-break-after:avoid" class="MsoNormal">
                                            <i>
                                                <span lang="NO-BOK">Eldre pasienter</span>
                                            </i>
                                        </p>
                                        <p style="line-height:normal;page-break-after:avoid" class="MsoNormal">
                                            <span lang="NO-BOK">Kliniske studier av Acme Product inkluderte ikke et tilstrekkelig antall pasienter i alderen 65 r og over for  kunne avgjre hvorvidt de responderer annerledes sammenlignet med pasienter under 65 r (se pkt. 5.2). Basert p farmakologien til dimetylfumarat, </span>
                                            <span lang="NO-BOK">er</span>
                                            <span lang="NO-BOK">et behov for justering av dosen hos eldre</span>
                                            <span lang="NO-BOK">ikke forventet</span>
                                            <span lang="NO-BOK">.</span>
                                        </p>
                                        <p style="line-height:normal" class="MsoNormal"/>
                                        <p style="line-height:normal;page-break-after:avoid" class="MsoNormal">
                                            <i>
                                                <span lang="NO-BOK">Nedsatt nyrefunksjon</span>
                                            </i>
                                        </p>
                                        <p style="line-height:normal;page-break-after:avoid" class="MsoNormal">
                                            <span lang="NO-BOK">Ingen dosejustering er ndvendig hos pasienter med mild til moderat nedsatt nyrefunksjon (se pkt. 5.2). Acme Product er ikke underskt hos pasienter med alvorlig nedsatt nyrefunksjon, og bruk av Acme Product er kontraindisert hos disse pasientene (se pkt. 4.3).</span>
                                        </p>
                                        <p style="line-height:normal" class="MsoNormal"/>
                                        <p style="line-height:normal;page-break-after:avoid" class="MsoNormal">
                                            <i>
                                                <span lang="NO-BOK">Nedsatt leverfunksjon</span>
                                            </i>
                                        </p>
                                        <p style="line-height:normal;page-break-after:avoid" class="MsoNormal">
                                            <span lang="NO-BOK">Ingen dosejustering er ndvendig hos pasienter med mild til moderat nedsatt leverfunksjon (se pkt. 5.2). Acme Product er ikke underskt hos pasienter med alvorlig nedsatt leverfunksjon, og bruken av Acme Product er kontraindisert hos disse pasientene (se pkt. 4.3).</span>
                                        </p>
                                        <p style="line-height:normal" class="MsoNormal"/>
                                    </div>
                </text>
                <section id="c9f25cf2-76f8-4f46-9e79-df85bb5185ed">
                  <title value="Pediatrisk populasjon"/>
                  <code>
                    <coding>
                      <system value="http://spor.ema.europa.eu/v1/example-sections"/>
                      <code value="13"/>
                      <display value="Pediatrisk populasjon"/>
                    </coding>
                  </code>
                  <text>
                    <status value="additional"/><div xmlns="http://www.w3.org/1999/xhtml">
                                            <p style="line-height:normal;page-break-after:avoid" class="MsoNormal">
                                                <span lang="NO-BOK">Sikkerhet og effekt av Acme Product hos den pediatriske populasjonen under en alder p 18 r har ikke blitt fastsltt. Det finnes ingen tilgjengelige data for Acme Product hos den pediatriske populasjonen.</span>
                                            </p>
                                            <p style="line-height:normal;text-autospace:none" class="MsoNormal"/>
                                        </div>
                  </text>
                </section>
              </section>
              <section id="82cfd9b0-45eb-46d7-921b-57ff3afd01c9">
                <title value="Administrasjonsm&#xE5;te"/>
                <code>
                  <coding>
                    <system value="http://spor.ema.europa.eu/v1/example-sections"/>
                    <code value="14"/>
                    <display value="Administrasjonsm&#xE5;te"/>
                  </coding>
                </code>
                <text>
                  <status value="additional"/><div xmlns="http://www.w3.org/1999/xhtml">
                                        <p style="line-height:normal;page-break-after:avoid" class="MsoNormal">
                                            <span lang="NO-BOK">Acme Product er til oral bruk. Acme Product-tablettene skal svelges hele med vske under eller rett etter et mltid.</span>
                                        </p>
                                        <p style="line-height:normal" class="MsoNormal">
                                            <u>
                                                <span lang="NO-BOK"/>
                                            </u>
                                        </p>
                                        <p style="line-height:normal" class="MsoNormal">
                                            <span lang="NO-BOK">Drasjeringen p enterotablettene er designet til  forhindre mageirritasjon. Derfor skal tablettene ikke knuses, deles, opplses eller tygges. </span>
                                        </p>
                                        <p style="line-height:normal" class="MsoNormal"/>
                                    </div>
                </text>
              </section>
            </section>
            <section id="c7ff6012-3955-41e9-829f-03258aec52c3">
              <title value="4.3     Kontraindikasjoner"/>
              <code>
                <coding>
                  <system value="http://spor.ema.europa.eu/v1/example-sections"/>
                  <code value="16"/>
                  <display value="4.3 Kontraindikasjoner"/>
                </coding>
              </code>
              <text>
                <status value="additional"/><div xmlns="http://www.w3.org/1999/xhtml">
                                    <p style="line-height:normal;page-break-after:avoid" class="MsoNormal"/>
                                    <p style="margin-top:0in;margin-right:0in;margin-bottom:  0in;margin-left:28.35pt;text-indent:-28.35pt;page-break-after:avoid" class="Listeavsnitt1">
                                        <span style="font-size:11.0pt;font-family:Symbol" lang="NO-BOK">-</span>
                                        <span style="font-size:11.0pt" lang="NO-BOK">Overflsomhet overfor virkestoffet eller overfor noen av hjelpestoffene listet opp i pkt. 6.1. </span>
                                    </p>
                                    <p style="margin-top:0in;margin-right:0in;margin-bottom:  0in;margin-left:28.35pt;text-indent:-28.35pt" class="Listeavsnitt1">
                                        <span style="font-size:11.0pt;font-family:Symbol" lang="NO-BOK">-</span>
                                        <span style="font-size:11.0pt" lang="NO-BOK">Alvorlige gastrointestinale sykdommer.</span>
                                    </p>
                                    <p style="margin-top:0in;margin-right:0in;margin-bottom:  0in;margin-left:28.35pt;text-indent:-28.35pt" class="Listeavsnitt1">
                                        <span style="font-size:11.0pt;font-family:Symbol" lang="NO-BOK">-</span>
                                        <span style="font-size:11.0pt" lang="NO-BOK">Alvorlig nedsatt lever- eller nyrefunksjon.</span>
                                    </p>
                                    <p style="margin-top:0in;margin-right:0in;margin-bottom:  0in;margin-left:28.35pt;text-indent:-28.35pt" class="Listeavsnitt1">
                                        <span style="font-size:11.0pt;font-family:Symbol" lang="NO-BOK">-</span>
                                        <span style="font-size:11.0pt" lang="NO-BOK">Graviditet og amming.</span>
                                    </p>
                                    <p style="line-height:normal" class="MsoNormal"/>
                                </div>
              </text>
            </section>
            <section id="590abf58-3378-437f-9015-57675c2a6b60">
              <title value="4.4     Advarsler og forsiktighetsregler"/>
              <code>
                <coding>
                  <system value="http://spor.ema.europa.eu/v1/example-sections"/>
                  <code value="17"/>
                  <display value="4.4 Advarsler og forsiktighetsregler"/>
                </coding>
              </code>
              <text>
                <status value="additional"/><div xmlns="http://www.w3.org/1999/xhtml">
                                    <p style="line-height:normal;page-break-after:avoid" class="MsoNormal">
                                        <u>
                                            <span lang="NO-BOK"/>
                                        </u>
                                    </p>
                                    <p style="line-height:normal;page-break-after:avoid" class="MsoNormal">
                                        <u>
                                            <span lang="NO-BOK">Hematologi</span>
                                        </u>
                                    </p>
                                    <p style="line-height:normal;page-break-after:avoid" class="MsoNormal">
                                        <span lang="NO-BOK">Acme Product kan redusere antall leukocytter og lymfocytter (se pkt. 4.8). Det har ikke blitt underskt hos pasienter med underliggende lavt leukocytt- eller lymfocyttall.</span>
                                    </p>
                                    <p style="line-height:normal" class="MsoNormal"/>
                                    <p style="line-height:normal;page-break-after:avoid" class="MsoNormal">
                                        <i>
                                            <span lang="NO-BOK">Fr </span>
                                        </i>
                                        <i>
                                            <span lang="NO-BOK">behandling</span>
                                        </i>
                                    </p>
                                    <p style="line-height:normal;page-break-after:avoid" class="MsoNormal">
                                        <span lang="NO-BOK">Fr oppstart av behandling med Acme Product, br en ny </span>
                                        <span lang="NO-BOK">fullstendig blodtelling</span>
                                        <span lang="NO-BOK">(herunder
differensialtelling og blodplater) vre tilgjengelig. Behandlingen skal ikke
initieres hvis leukopeni under 3,0 x 10
                                            <sup>9</sup>/l, lymfopeni under 1,0 x 10
                                            <sup>9</sup>/l
eller andre patologiske resultater identifiseres.
                                        </span>
                                    </p>
                                    <p style="line-height:normal" class="MsoNormal"/>
                                    <p style="line-height:normal;page-break-after:avoid" class="MsoNormal">
                                        <i>
                                            <span lang="NO-BOK">Under behandling</span>
                                        </i>
                                    </p>
                                    <p style="line-height:normal;page-break-after:avoid" class="MsoNormal">
                                        <span lang="NO-BOK">Under behandling skal en fullstendig blodtelling med differensialtelling utfres hver 3. mned. Det kreves tiltak ved flgende forhold:</span>
                                    </p>
                                    <p style="line-height:normal" class="MsoNormal"/>
                                    <p style="line-height:normal" id="bffaa942-5ceb-40b6-9e61-5ff98c72b82a" class="MsoNormal"/>
                                    <i>
                                        <span lang="NO-BOK">Leukopeni:</span>
                                    </i>
                                    <none/>
                                    <p style="line-height:normal" id="bffaa942-5ceb-40b6-9e61-5ff98c72b82a" class="MsoNormal">
                                        <span lang="NO-BOK">Hvis det blir funnet en markert nedgang i totalt antallleukocytter, br situasjonen overvkes nye og behandling med Acme Product br avbrytesved niver under 3,0 x 10
                                            <sup>9</sup>/l.
                                        </span>
                                    </p>
                                    <p style="line-height:normal" class="MsoNormal"/>
                                    <p style="line-height:normal" id="4c859ed4-dc2a-460d-bd1e-11830edbfffa" class="MsoNormal"/>
                                    <i>
                                        <span lang="NO-BOK">Lymfopeni:</span>
                                    </i>
                                    <none/>
                                    <p style="line-height:normal" id="4c859ed4-dc2a-460d-bd1e-11830edbfffa" class="MsoNormal">
                                        <span lang="NO-BOK">Hvis lymfocyttnivet faller under 1,0 x 10
                                            <sup>9</sup>/l, men er 0,7 x 10
                                            <sup>9</sup>/l, skal blodovervkning utfres mnedlig inntilniver returnerer til 1,0 x 10
                                            <sup>9</sup>/l eller hyere ved to pflgendeblodprver, og fra dette tidspunktet kan overvkningen igjen utfres hver 3.mned.
                                        </span>
                                    </p>
                                    <p style="line-height:normal" class="MsoNormal">
                                        <span lang="NO-BOK">Hvis
lymfocyttnivet faller under 0,7 x 10
                                            <sup>9</sup>/l, m blodprven gjentas, og
hvis nivene bekreftes  vre under 0,7 x 10
                                            <sup>9</sup>, m behandlingen
stoppes umiddelbart.
                                        </span>
                                    </p>
                                    <p style="line-height:normal" class="MsoNormal">
                                        <span lang="NO-BOK">Pasienter som utvikler lymfopeni, skal overvkes etter  ha avsluttet behandlingen inntil lymfocyttnivet har gtt tilbake til normalomrdet (se pkt. 4.8).</span>
                                    </p>
                                    <p style="line-height:normal" class="MsoNormal"/>
                                    <p style="line-height:normal;page-break-after:avoid" class="MsoNormal">
                                        <i>
                                            <span lang="NO-BOK">Andre hematologiske sykdommer</span>
                                        </i>
                                    </p>
                                    <p style="line-height:normal;page-break-after:avoid" class="MsoNormal">
                                        <span lang="NO-BOK">Behandlingen skal avbrytes og det anbefales  utvise forsiktighet hvis andre patologiske resultater forekommer. I alle fall skal blodnivene overvkes inntil verdiene har gtt tilbake til normalomrdet.</span>
                                    </p>
                                    <p style="line-height:normal" class="MsoNormal"/>
                                    <p style="line-height:normal" class="MsoNormal">
                                        <u>
                                            <span lang="NO-BOK">Infeksjoner</span>
                                        </u>
                                    </p>
                                    <p style="line-height:normal" class="MsoNormal">
                                        <span lang="NO-BOK">Acme Product er en immunmodulator og kan pvirke hvordan immunsystemet reagerer p infeksjoner. For pasienter med eksisterende infeksjoner av klinisk relevans, skal legen avgjre om behandling med Acme Product frst skal initieres nr infeksjonen er over. Hvis en pasient utvikler en infeksjon under behandlingen med Acme Product, skal en utsettelse av behandlingen vurderes, og fordelene og risikoene skal revurderes fr behandlingen pbegynnes p nytt. Pasienter som mottar Acme Product skal instrueres til  rapportere symptomer p infeksjon til en lege.</span>
                                    </p>
                                    <p style="line-height:normal" class="MsoNormal"/>
                                    <p style="line-height:normal;page-break-after:avoid" class="MsoNormal">
                                        <i>
                                            <span lang="NO-BOK">Opportunistiske infeksjoner / progressiv multifokal leukoencefalopati (PML)</span>
                                        </i>
                                    </p>
                                    <p style="line-height:normal;page-break-after:avoid" class="MsoNormal">
                                        <span lang="NO-BOK">Tilfeller av opportunistiske infeksjoner, spesielt progressiv multifokal leukoencefalopati (PML) har blitt rapporter med andre dimetylfumaratholdige legemidler (se pkt. 4.8). PML er en opportunistisk infeksjon forrsaket av John-Cunningham-virus (JCV) som kan vre ddelig eller forrsake alvorlige funksjonshemminger. PML er sannsynligvis forrsaket av en kombinasjon av faktorer.</span>
                                    </p>
                                    <p style="line-height:normal" class="MsoNormal"/>
                                    <p style="line-height:normal" class="MsoNormal">
                                        <span lang="NO-BOK">En tidligere infeksjon med JCV anses som en forutsetning for utvikling av PML. Risikofaktorer kan inkludere tidligere immunsuppressiv behandling og eksistensen av visse samtidige sykdommer (slik som autoimmune sykdommer eller ondartede hematologiske tilstander). Et modifisert eller svekket immunsystem, samt genetiske eller miljmessige faktorer kan ogs utgjre risikofaktorer.</span>
                                    </p>
                                    <p style="line-height:normal" class="MsoNormal"/>
                                    <p style="line-height:normal" class="MsoNormal">
                                        <span lang="NO-BOK">Vedvarende moderat eller alvorlig lymfopeni i lpet av behandling med dimetylfumarat anses ogs som en risikofaktor for PML. Pasienter som utvikler lymfopeni skal overvkes for tegn og symptomer p opportunistiske infeksjoner, spesielt symptomer som tyder p PML. Typiske symptomer assosiert med PML er mangfoldige, blir verre over dager til uker og inkluderer progressiv svakhet p n side av kroppen eller klumsethet i lemmene, synsforstyrrelse og endringer i tankegang, minne og orientering, noe som frer til forvirring og personlighetsforandringer. Hvis det mistenkes PML, skal behandlingen med Acme Product stoppes umiddelbart og ytterligere egnede nevrologiske og radiologiske underskelser gjennomfres.</span>
                                    </p>
                                    <p style="line-height:normal" class="MsoNormal"/>
                                    <p style="line-height:normal;page-break-after:avoid" class="MsoNormal">
                                        <u>
                                            <span lang="NO-BOK">Tidligere og samtidig behandling med immunsuppressive eller immunmodulerende behandlinger</span>
                                        </u>
                                    </p>
                                    <p style="line-height:normal;page-break-after:avoid" class="MsoNormal">
                                        <span lang="NO-BOK">Det finnes begrensede data tilgjengelig om effekten og sikkerheten til Acme Product hos pasienter som tidligere har blitt behandlet med immunsuppressive eller immunmodulerende behandlinger. Nr pasienter bytter fra slike behandlinger til Acme Product, skal halveringstiden og virkemten til den andre behandlingen vurderes for  unng additive virkninger p immunsystemet.</span>
                                    </p>
                                    <p style="line-height:normal" class="MsoNormal"/>
                                    <p style="line-height:normal" class="MsoNormal">
                                        <span lang="NO-BOK">Det finnes ingen tilgjengelige data om effekten og sikkerheten til Acme Product nr det tas samtidig med andre immunsuppressive eller immunmodulerende behandlinger (se pkt. 4.5).</span>
                                    </p>
                                    <p style="line-height:normal" class="MsoNormal"/>
                                    <p style="line-height:normal;page-break-after:avoid" class="MsoNormal">
                                        <u>
                                            <span lang="NO-BOK">Eksisterende gastrointestinal sykdom</span>
                                        </u>
                                    </p>
                                    <p style="line-height:normal;page-break-after:avoid" class="MsoNormal">
                                        <span lang="NO-BOK">Acme Product har ikke blitt studert hos pasienter med eksisterende gastrointestinal sykdom. Acme Product er kontraindisert hos pasienter med alvorlig gastrointestinal sykdom (se pkt. 4.3). Gastrointestinal toleranse kan forbedres ved  flge dosetitreringsplanen ved oppstart av Acme Product-behandlingen og ved  ta Acme Product med mat (se pkt. 4.2 og 4.8).</span>
                                    </p>
                                    <p style="line-height:normal" class="MsoNormal"/>
                                    <p style="line-height:normal;page-break-after:avoid" class="MsoNormal">
                                        <u>
                                            <span lang="NO-BOK">Nyrefunksjon</span>
                                        </u>
                                    </p>
                                    <p style="line-height:normal;page-break-after:avoid" class="MsoNormal">
                                        <span lang="NO-BOK">Siden eliminasjon via nyrene spiller en mindre rolle i Acme Products plasmaclearance, er det lite sannsynlig at nedsatt nyrefunksjon ville innvirke p de farmakokinetiske egenskapene, og det forventes derfor at en dosejustering ikke er ndvendig for pasienter med mild til moderat nedsatt nyrefunksjon (se pkt. 4.2 og 5.2). </span>
                                    </p>
                                    <p style="line-height:normal" class="MsoNormal"/>
                                    <p style="line-height:normal" class="MsoNormal">
                                        <span lang="NO-BOK">I lpet av den placebokontrollerte, kliniske fase III-studien ble det ikke observert noen svekking av nyrefunksjon under behandling p tvers av behandlingsgruppene. Acme Product har imidlertid ikke blitt underskt hos pasienter med alvorlig nedsatt nyrefunksjon, og noen tilfeller av nyretoksisitet har blitt rapportert under overvkning etter markedsfring med fumarsyreestere. Dermed er Acme Product kontraindisert hos pasienter med alvorlig nedsatt nyrefunksjon (se pkt. 4.3). </span>
                                    </p>
                                    <p style="line-height:normal" class="MsoNormal"/>
                                    <p style="line-height:normal" class="MsoNormal">
                                        <span lang="NO-BOK">Nyrefunksjon (f.eks. kreatinin, blodureanitrogen og urinanalyse) skal sjekkes fr behandlingsstart og hver 3. mned deretter. I tilfelle av en klinisk relevant endring i nyrefunksjon, spesielt i fravr av alternative forklaringer, br dosereduksjon eller behandlingsseponering vurderes. </span>
                                    </p>
                                    <p style="line-height:normal" class="MsoNormal"/>
                                    <p style="line-height:normal;page-break-after:avoid" class="MsoNormal">
                                        <i>
                                            <span lang="NO-BOK">Fanconi-syndrom</span>
                                        </i>
                                    </p>
                                    <p style="line-height:normal;page-break-after:avoid" class="MsoNormal">
                                        <span lang="NO-BOK">Tidlig diagnostisering av Fanconi-syndrom og seponering av Acme Product-behandling er viktig for  forhindre start av nedsatt nyrefunksjon og osteomalasi, da syndromet vanligvis er reversibelt. De viktigste tegnene er: proteinuri, glukosuri (med normale blodsukkerniver), hyperaminoaciduri og fosfaturi (mulig samtidig med hypofosfatemi). Progresjon kan involvere symptomer som polyuri, polydipsi og proksimal muskelsvakhet. I sjeldne tilfeller kan hypofosfatemisk osteomalasi med ikke-lokaliserte skjelettsmerter, forhyet alkalisk fosfatase i serum og stressfraktuer oppst. Det er viktig  merke seg at Fanconi-syndrom kan forekomme uten forhyede kreatininniver eller lav glomerulr filtreringshastighet. I tilfelle uklare symptomer skal Fanconi-syndromet vurderes, og egnede underskelser m utfres.</span>
                                    </p>
                                    <p style="line-height:normal" class="MsoNormal"/>
                                    <p style="line-height:normal;page-break-after:avoid" class="MsoNormal">
                                        <u>
                                            <span lang="NO-BOK">Leverfunksjon</span>
                                        </u>
                                    </p>
                                    <p style="line-height:normal;page-break-after:avoid" class="MsoNormal">
                                        <span lang="NO-BOK">Acme Product har ikke blitt studert hos pasienter med alvorlig nedsatt leverfunksjon og er kontraindisert hos disse pasientene (se pkt. 4.3).</span>
                                    </p>
                                    <p style="line-height:normal" class="MsoNormal">
                                        <u>
                                            <span lang="NO-BOK"/>
                                        </u>
                                    </p>
                                    <p style="line-height:normal" class="MsoNormal">
                                        <span lang="NO-BOK">Det anbefales  overvke leverfunksjon (ASAT, ALAT, gamma-GT, AP) fr behandlingsstart og hver 3. mned deretter, siden kning av leverenzymer har blitt observert hos enkelte pasienter i fase III-studien. Skulle det oppst en klinisk relevant endring i leverparametrene, spesielt i fravr av alternative forklaringer, br dosereduksjon eller behandlingsseponering vurderes. </span>
                                    </p>
                                    <p style="line-height:normal" class="MsoNormal"/>
                                    <p style="line-height:normal;page-break-after:avoid" class="MsoNormal">
                                        <u>
                                            <span lang="NO-BOK">Rdme/flushing</span>
                                        </u>
                                    </p>
                                    <p style="line-height:normal;page-break-after:avoid" class="MsoNormal">
                                        <span lang="NO-BOK">Pasienter br gjres oppmerksom p at de sannsynligvis vil oppleve rdme de frste ukene de tar Acme Product (se pkt. 4.8). </span>
                                    </p>
                                    <p style="line-height:normal" class="MsoNormal"/>
                                    <p style="line-height:normal;page-break-after:avoid" class="MsoNormal">
                                        <u>
                                            <span lang="NO-BOK">Laktose</span>
                                        </u>
                                    </p>
                                    <p style="line-height:normal;page-break-after:avoid" class="MsoNormal">
                                        <span lang="NO-BOK">Acme Product inneholder laktose. Pasienter med sjeldne arvelige problemer med galaktoseintoleranse, total laktasemangel eller glukose-galaktose-malabsorpsjon, br ikke ta dette legemidlet.</span>
                                    </p>
                                    <p style="line-height:normal" class="MsoNormal"/>
                                </div>
              </text>
            </section>
            <section id="beb6b712-37af-432a-901f-ab710741e677">
              <title value="4.5     Interaksjon med andre legemidler og andre former for interaksjon"/>
              <code>
                <coding>
                  <system value="http://spor.ema.europa.eu/v1/example-sections"/>
                  <code value="20"/>
                  <display value="4.5 Interaksjon med andre legemidler og andre former for interaksjon"/>
                </coding>
              </code>
              <text>
                <status value="additional"/><div xmlns="http://www.w3.org/1999/xhtml">
                                    <p style="line-height:normal;page-break-after:avoid" class="MsoNormal"/>
                                    <p style="line-height:normal;page-break-after:avoid" class="MsoNormal">
                                        <span lang="NO-BOK">Ingen interaksjonsstudier er blitt utfrt.</span>
                                    </p>
                                    <p style="line-height:normal" class="MsoNormal"/>
                                    <p style="line-height:normal" class="MsoNormal">
                                        <span lang="NO-BOK">Acme Product br derfor brukes med forsiktighet i kombinasjon med annen systemisk psoriasisbehandling (f.eks. metotreksat, retinoider, psoralener, ciklosporin, immunsuppressiva eller cytostatika) (se pkt. 4.4). Samtidig bruk av andre fumarsyrederivater under behandlingen med Acme Product br unngs (topikale eller systemiske). </span>
                                    </p>
                                    <p style="line-height:normal" class="MsoNormal"/>
                                    <p style="line-height:normal" class="MsoNormal">
                                        <span lang="NO-BOK">Samtidig behandling med nyretoksiske stoffer (f.eks. metotreksat, ciklosporin, aminoglykosider, diuretika, NSAID-er eller litium) kan ke potensialet for nyrebivirkninger (f.eks. proteinuri) hos pasienter som tar Acme Product.</span>
                                    </p>
                                    <p style="line-height:normal" class="MsoNormal"/>
                                    <p style="line-height:normal" class="MsoNormal">
                                        <span lang="NO-BOK">I tilfelle av alvorlig eller langvarig diar under behandling med Acme Product, kan absorpsjonen av andre legemidler pvirkes. Forsiktighet br utvises nr legemidler med en smal terapeutisk indeks som krever absorpsjon i tarmen skal foreskrives. Effekten til orale prevensjonsmidler kan vre redusert, og bruken av et alternativt barriereprevensjonsmiddel anbefales for  forhindre mulig prevensjonssvikt (se forskrivningsinformasjon for oralt prevensjonsmiddel).</span>
                                    </p>
                                    <p style="line-height:normal" class="MsoNormal"/>
                                    <p style="line-height:normal" class="MsoNormal">
                                        <span lang="NO-BOK">Inntak av store mengder sterke alkoholholdige drikkevarer (mer enn 30 vol. % alkohol) skal unngs, da dette kan fre til kt opplsningshastighet for Acme Product og derfor kan ke frekvensen av gastrointestinale bivirkninger.</span>
                                    </p>
                                    <p style="line-height:normal" class="MsoNormal"/>
                                    <p style="line-height:normal" class="MsoNormal">
                                        <span lang="NO-BOK">Vaksinering under behandling med Acme Product har ikke blitt studert. Immunsuppressjon er en risikofaktor for bruk av levende vaksiner. Risikoen ved vaksinering skal vurderes opp mot fordelen.</span>
                                    </p>
                                    <p style="line-height:normal" class="MsoNormal"/>
                                    <p style="line-height:normal" class="MsoNormal">
                                        <span lang="NO-BOK">Det finnes ingen tegn p Acme Product-interaksjon med cytokrom P450 og de mest vanlige effluks- og opptakstransportrene, dermed forventes ingen interaksjoner med legemidler som metaboliseres eller transporteres av disse systemene (se pkt. 5.2)</span>
                                    </p>
                                    <p style="line-height:normal" class="MsoNormal"/>
                                </div>
              </text>
            </section>
            <section id="b769313d-03f5-4684-bedf-6c423bb88dc5">
              <title value="4.6     Fertilitet, graviditet og amming"/>
              <code>
                <coding>
                  <system value="http://spor.ema.europa.eu/v1/example-sections"/>
                  <code value="22"/>
                  <display value="4.6 Fertilitet, graviditet og amming"/>
                </coding>
              </code>
              <text>
                <status value="additional"/><div xmlns="http://www.w3.org/1999/xhtml">
                                    <p style="line-height:normal;page-break-after:avoid" class="MsoCommentText">
                                        <u>
                                            <span style="font-size:11.0pt" lang="NO-BOK"/>
                                        </u>
                                    </p>
                                    <p style="line-height:normal;page-break-after:avoid" class="MsoCommentText">
                                        <u>
                                            <span style="font-size:11.0pt" lang="NO-BOK">Fertile kvinner</span>
                                        </u>
                                    </p>
                                    <p style="line-height:normal;page-break-after:avoid" class="MsoCommentText">
                                        <span style="font-size:11.0pt" lang="NO-BOK">Acme Product er ikke anbefalt hos fertile kvinner som ikke bruker egnet prevensjon. Hos pasienter som opplever diar under Acme Product-behandling, kan effekten av orale prevensjonsmidler vre redusert, og det kan vre ndvendig med barrieremetoder for prevensjon i tillegg (se pkt. 4.5).</span>
                                    </p>
                                    <p style="line-height:normal" class="MsoCommentText">
                                        <u>
                                            <span style="font-size:11.0pt" lang="NO-BOK"/>
                                        </u>
                                    </p>
                                </div>
              </text>
              <section id="e60acf54-e90b-4d06-971a-5219abe3df44">
                <title value="Graviditet"/>
                <code>
                  <coding>
                    <system value="http://spor.ema.europa.eu/v1/example-sections"/>
                    <code value="23"/>
                    <display value="Graviditet"/>
                  </coding>
                </code>
                <text>
                  <status value="additional"/><div xmlns="http://www.w3.org/1999/xhtml">
                                        <p style="line-height:normal;page-break-after:avoid" class="MsoNormal">
                                            <span lang="NO-BOK">Det foreligger begrenset mengde data p bruk av dimetylfumarat hos gravide kvinner. Studier p dyr har vist reproduksjonstoksisitet (se pkt. 5.3). Acme Product er kontraindisert ved graviditet (se pkt. 4.3). </span>
                                        </p>
                                        <p style="line-height:normal" class="MsoNormal">
                                            <u>
                                                <span lang="NO-BOK"/>
                                            </u>
                                        </p>
                                    </div>
                </text>
              </section>
              <section id="60cdd509-a45c-4a68-ab36-32bda631bddd">
                <title value="Amming"/>
                <code>
                  <coding>
                    <system value="http://spor.ema.europa.eu/v1/example-sections"/>
                    <code value="24"/>
                    <display value="Amming"/>
                  </coding>
                </code>
                <text>
                  <status value="additional"/><div xmlns="http://www.w3.org/1999/xhtml">
                                        <p style="line-height:normal;page-break-after:avoid" class="MsoNormal">
                                            <span style="color:black" lang="NO-BOK">Det er ukjent om </span>
                                            <span lang="NO-BOK">dimetylfumarat
                                                <span style="color:black">/metabolitter blir skilt ut i morsmelk hos mennesker. En risiko for nyfdte eller spedbarn som ammes kan ikke </span>utelukkes
                                                <span style="color:black">.</span>Derfor er Acme Product kontraindisert ved amming (se
pkt. 4.3).
                                            </span>
                                        </p>
                                        <p style="line-height:normal" class="MsoCommentText"/>
                                    </div>
                </text>
              </section>
              <section id="3edf109d-a075-49d3-9e8e-291af2f7af8a">
                <title value="Fertilitet"/>
                <code>
                  <coding>
                    <system value="http://spor.ema.europa.eu/v1/example-sections"/>
                    <code value="25"/>
                    <display value="Fertilitet"/>
                  </coding>
                </code>
                <text>
                  <status value="additional"/><div xmlns="http://www.w3.org/1999/xhtml">
                                        <p style="line-height:normal;page-break-after:avoid" class="MsoNormal">
                                            <span lang="NO-BOK">Det foreligger ingen data for mennesker eller dyr p effekten av Acme Product p fertilitet. </span>
                                        </p>
                                        <p style="line-height:normal" class="MsoNormal"/>
                                    </div>
                </text>
              </section>
            </section>
            <section id="8ede57fa-b7f5-40aa-8b99-8782edf4914e">
              <title value="4.7     P&#xE5;virkning av evnen til &#xE5; kj&#xF8;re bil og bruke maskiner"/>
              <code>
                <coding>
                  <system value="http://spor.ema.europa.eu/v1/example-sections"/>
                  <code value="26"/>
                  <display value="4.7 P&#xE5;virkning av evnen til &#xE5; kj&#xF8;re bil og bruke maskiner"/>
                </coding>
              </code>
              <text>
                <status value="additional"/><div xmlns="http://www.w3.org/1999/xhtml">
                                    <p style="line-height:normal;page-break-after:avoid" class="MsoNormal"/>
                                    <p style="line-height:normal;page-break-after:avoid" class="MsoNormal">
                                        <span lang="NO-BOK">Det er ikke gjennomfrt noen studier av evnen til  kjre bil og bruke maskiner. Acme Product kan ha </span>
                                        <span lang="NO-BOK">en </span>
                                        <span lang="NO-BOK">liten pvirkning p evnen til  kjre bil og bruke maskiner. Svimmelhet og tretthet kan forekomme etter administrering av Acme Product (se pkt. 4.8).</span>
                                    </p>
                                    <p style="line-height:normal" class="MsoNormal"/>
                                </div>
              </text>
            </section>
            <section id="779ba6b9-7eeb-47ed-891d-8245b11c1093">
              <title value="4.8     Bivirkninger"/>
              <code>
                <coding>
                  <system value="http://spor.ema.europa.eu/v1/example-sections"/>
                  <code value="27"/>
                  <display value="4.8 Bivirkninger"/>
                </coding>
              </code>
              <text>
                <status value="additional"/><div xmlns="http://www.w3.org/1999/xhtml">
                                    <p style="line-height:normal;page-break-after:avoid" class="MsoNormal">
                                        <u>
                                            <span lang="NO-BOK"/>
                                        </u>
                                    </p>
                                    <p style="line-height:normal;page-break-after:avoid" class="MsoNormal">
                                        <u>
                                            <span lang="NO-BOK">Sammendrag av sikkerhetsprofilen</span>
                                        </u>
                                    </p>
                                    <p style="line-height:normal;page-break-after:avoid" class="MsoNormal">
                                        <span lang="NO-BOK">De vanligste bivirkningene observert med Acme Product i den kliniske fase III-studien (1102) hos psoriasispasienter var gastrointestinale hendelser (62,7 %), rdme (20,8 %) og lymfopeni (10 %). De fleste bivirkningene ble ansett for  vre milde og frte ikke til seponering av studiebehandlingen. De eneste bivirkningene som frte til seponering av behandling for &gt;5 % av pasientene var gastrointestinale reaksjoner. For overvkningsanbefalinger og klinisk hndtering av bivirkninger, se pkt. 4.4. </span>
                                    </p>
                                    <p style="line-height:normal" class="MsoNormal"/>
                                    <p style="line-height:normal;page-break-after:avoid" class="MsoNormal">
                                        <u>
                                            <span lang="NO-BOK">Bivirkningstabell</span>
                                        </u>
                                    </p>
                                    <p style="line-height:normal;page-break-after:avoid" class="MsoNormal">
                                        <span lang="NO-BOK">Flgende er en liste over bivirkninger som pasienter opplevde under behandling med Acme Product i lpet av den kliniske studien og med Fumaderm, et relatert legemiddel som inneholder dimetylfumarat samt andre fumarsyreestere.</span>
                                    </p>
                                    <p style="line-height:normal" class="MsoNormal"/>
                                    <p style="line-height:normal" class="MsoNormal">
                                        <span lang="NO-BOK">Bivirkningsfrekvensen er definert ved hjelp av flgende konvensjon: svrt vanlige ( 1/10), vanlige ( 1/100 til &lt;1/10), mindre vanlige ( 1/1000 til &lt;1/100), sjeldne ( 1/10 000 til &lt;1/1000), svrt sjeldne (&lt;1/10 000) og ikke kjent (kan ikke ansls utfra tilgjengelige data). </span>
                                    </p>
                                    <p style="line-height:normal" class="MsoNormal"/>
                                    <table border="1" cellpadding="0" cellspacing="0" style="border-collapse:collapse;border:none" class="MsoNormalTable">
                                        <thead>
                                            <tr>
                                                <td width="207" style="width:155.35pt;border:solid windowtext 1.0pt;     padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top">
                                                    <p style="line-height:normal" class="MsoNormal">
                                                        <b>
                                                            <span lang="NO-BOK">Organklassesystem</span>
                                                        </b>
                                                    </p>
                                                </td>
                                                <td width="206" style="width:2.15in;border:solid windowtext 1.0pt;     border-left:none;padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top">
                                                    <p style="line-height:normal" class="MsoNormal">
                                                        <b>
                                                            <span lang="NO-BOK">Bivirkninger</span>
                                                        </b>
                                                    </p>
                                                </td>
                                                <td width="206" style="width:154.2pt;border:solid windowtext 1.0pt;     border-left:none;padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top">
                                                    <p style="line-height:normal" class="MsoNormal">
                                                        <b>
                                                            <span lang="NO-BOK">Frekvens</span>
                                                        </b>
                                                    </p>
                                                </td>
                                            </tr>
                                        </thead>
                                        <tr>
                                            <td width="207" style="width:155.35pt;border:solid windowtext 1.0pt;    border-top:none;padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top">
                                                <p style="line-height:normal" class="MsoNormal">
                                                    <span lang="NO-BOK">Infeksise og   parasittre sykdommer</span>
                                                </p>
                                            </td>
                                            <td width="206" style="width:2.15in;border-top:none;border-left:    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top">
                                                <p style="line-height:normal" class="MsoNormal">
                                                    <span lang="NO-BOK">Herpes zoster</span>
                                                </p>
                                            </td>
                                            <td width="206" style="width:154.2pt;border-top:none;border-left:    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top">
                                                <p style="line-height:normal" class="MsoNormal">
                                                    <span lang="NO-BOK">Ikke kjent**</span>
                                                </p>
                                            </td>
                                        </tr>
                                        <tr>
                                            <td width="207" style="width:155.35pt;border:solid windowtext 1.0pt;    border-top:none;padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top">
                                                <p style="line-height:normal" class="MsoNormal">
                                                    <span lang="NO-BOK">Sykdommer i   blod og lymfatiske organer</span>
                                                </p>
                                            </td>
                                            <td width="206" style="width:2.15in;border-top:none;border-left:    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top">
                                                <p style="line-height:normal" class="MsoNormal">
                                                    <span lang="NO-BOK">Lymfopeni</span>
                                                </p>
                                                <p style="line-height:normal" class="MsoNormal">
                                                    <span lang="NO-BOK">Leukopeni</span>
                                                </p>
                                                <p style="line-height:normal" class="MsoNormal">
                                                    <span lang="NO-BOK">Eosinofili</span>
                                                </p>
                                                <p style="line-height:normal" class="MsoNormal">
                                                    <span lang="NO-BOK">Leukocytose</span>
                                                </p>
                                                <p style="line-height:normal" class="MsoNormal">
                                                    <span lang="NO-BOK">Akutt   lymfatisk leukemi*</span>
                                                </p>
                                                <p style="line-height:normal" class="MsoNormal">
                                                    <span lang="NO-BOK">Irreversibel   pancytopeni*</span>
                                                </p>
                                            </td>
                                            <td width="206" style="width:154.2pt;border-top:none;border-left:    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top">
                                                <p style="line-height:normal" class="MsoNormal">
                                                    <span lang="NO-BOK">Svrt vanlige</span>
                                                </p>
                                                <p style="line-height:normal" class="MsoNormal">
                                                    <span lang="NO-BOK">Svrt vanlige</span>
                                                </p>
                                                <p style="line-height:normal" class="MsoNormal">
                                                    <span lang="NO-BOK">Vanlige</span>
                                                </p>
                                                <p style="line-height:normal" class="MsoNormal">
                                                    <span lang="NO-BOK">Vanlige</span>
                                                </p>
                                                <p style="line-height:normal" class="MsoNormal">
                                                    <span lang="NO-BOK">Svrt sjeldne</span>
                                                </p>
                                                <p style="line-height:normal" class="MsoNormal">
                                                    <span lang="NO-BOK">Svrt sjeldne</span>
                                                </p>
                                            </td>
                                        </tr>
                                        <tr>
                                            <td width="207" style="width:155.35pt;border:solid windowtext 1.0pt;    border-top:none;padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top">
                                                <p style="line-height:normal" class="MsoNormal">
                                                    <span lang="NO-BOK">Stoffskifte-   og ernringsbetingede sykdommer</span>
                                                </p>
                                            </td>
                                            <td width="206" style="width:2.15in;border-top:none;border-left:    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top">
                                                <p style="line-height:normal" class="MsoNormal">
                                                    <span lang="NO-BOK">Nedsatt   appetitt</span>
                                                </p>
                                            </td>
                                            <td width="206" style="width:154.2pt;border-top:none;border-left:    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top">
                                                <p style="line-height:normal" class="MsoNormal">
                                                    <span lang="NO-BOK">Vanlige</span>
                                                </p>
                                            </td>
                                        </tr>
                                        <tr>
                                            <td width="207" style="width:155.35pt;border:solid windowtext 1.0pt;    border-top:none;padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top">
                                                <p style="line-height:normal" class="MsoNormal">
                                                    <span lang="NO-BOK">Nevrologiske   sykdommer</span>
                                                </p>
                                            </td>
                                            <td width="206" style="width:2.15in;border-top:none;border-left:    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top">
                                                <p style="line-height:normal" class="MsoNormal">
                                                    <span lang="NO-BOK">Hodepine</span>
                                                </p>
                                                <p style="line-height:normal" class="MsoNormal">
                                                    <span lang="NO-BOK">Parestesi</span>
                                                </p>
                                                <p style="line-height:normal" class="MsoNormal">
                                                    <span lang="NO-BOK">Svimmelhet*</span>
                                                </p>
                                                <p style="line-height:normal" class="MsoNormal">
                                                    <span lang="NO-BOK">Progressiv   multifokal leukoencefalopati</span>
                                                </p>
                                            </td>
                                            <td width="206" style="width:154.2pt;border-top:none;border-left:    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top">
                                                <p style="line-height:normal" class="MsoNormal">
                                                    <span lang="NO-BOK">Vanlige</span>
                                                </p>
                                                <p style="line-height:normal" class="MsoNormal">
                                                    <span lang="NO-BOK">Vanlige</span>
                                                </p>
                                                <p style="line-height:normal" class="MsoNormal">
                                                    <span lang="NO-BOK">Mindre   vanlige</span>
                                                </p>
                                                <p style="line-height:normal" class="MsoNormal">
                                                    <span lang="NO-BOK">Ikke kjent</span>
                                                </p>
                                            </td>
                                        </tr>
                                        <tr>
                                            <td width="207" style="width:155.35pt;border:solid windowtext 1.0pt;    border-top:none;padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top">
                                                <p style="line-height:normal" class="MsoNormal">
                                                    <span lang="NO-BOK">Karsykdommer</span>
                                                </p>
                                            </td>
                                            <td width="206" style="width:2.15in;border-top:none;border-left:    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top">
                                                <p style="line-height:normal" class="MsoNormal">
                                                    <span lang="NO-BOK">Rdme/flushing</span>
                                                </p>
                                            </td>
                                            <td width="206" style="width:154.2pt;border-top:none;border-left:    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top">
                                                <p style="line-height:normal" class="MsoNormal">
                                                    <span lang="NO-BOK">Svrt vanlige</span>
                                                </p>
                                            </td>
                                        </tr>
                                        <tr>
                                            <td width="207" style="width:155.35pt;border:solid windowtext 1.0pt;    border-top:none;padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top">
                                                <p style="line-height:normal" class="MsoNormal">
                                                    <span lang="NO-BOK">Gastrointestinale   sykdommer</span>
                                                </p>
                                            </td>
                                            <td width="206" style="width:2.15in;border-top:none;border-left:    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top">
                                                <p style="line-height:normal" class="MsoNormal">
                                                    <span lang="NO-BOK">Diar</span>
                                                </p>
                                                <p style="line-height:normal" class="MsoNormal">
                                                    <span lang="NO-BOK">Abdominal   distensjon</span>
                                                </p>
                                                <p style="line-height:normal" class="MsoNormal">
                                                    <span lang="NO-BOK">Magesmerter</span>
                                                </p>
                                                <p style="line-height:normal" class="MsoNormal">
                                                    <span lang="NO-BOK">Kvalme</span>
                                                </p>
                                                <p style="line-height:normal" class="MsoNormal">
                                                    <span lang="NO-BOK">Oppkast</span>
                                                </p>
                                                <p style="line-height:normal" class="MsoNormal">
                                                    <span lang="NO-BOK">Dyspepsi</span>
                                                </p>
                                                <p style="line-height:normal" class="MsoNormal">
                                                    <span lang="NO-BOK">Forstoppelse</span>
                                                </p>
                                                <p style="line-height:normal" class="MsoNormal">
                                                    <span lang="NO-BOK">Ubehag i   magen</span>
                                                </p>
                                                <p style="line-height:normal" class="MsoNormal">
                                                    <span lang="NO-BOK">Flatulens</span>
                                                </p>
                                            </td>
                                            <td width="206" style="width:154.2pt;border-top:none;border-left:    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top">
                                                <p style="line-height:normal" class="MsoNormal">
                                                    <span lang="NO-BOK">Svrt vanlige</span>
                                                </p>
                                                <p style="line-height:normal" class="MsoNormal">
                                                    <span lang="NO-BOK">Svrt vanlige</span>
                                                </p>
                                                <p style="line-height:normal" class="MsoNormal">
                                                    <span lang="NO-BOK">Svrt vanlige</span>
                                                </p>
                                                <p style="line-height:normal" class="MsoNormal">
                                                    <span lang="NO-BOK">Svrt vanlige</span>
                                                </p>
                                                <p style="line-height:normal" class="MsoNormal">
                                                    <span lang="NO-BOK">Vanlige</span>
                                                </p>
                                                <p style="line-height:normal" class="MsoNormal">
                                                    <span lang="NO-BOK">Vanlige</span>
                                                </p>
                                                <p style="line-height:normal" class="MsoNormal">
                                                    <span lang="NO-BOK">Vanlige</span>
                                                </p>
                                                <p style="line-height:normal" class="MsoNormal">
                                                    <span lang="NO-BOK">Vanlige</span>
                                                </p>
                                                <p style="line-height:normal" class="MsoNormal">
                                                    <span lang="NO-BOK">Vanlige</span>
                                                </p>
                                            </td>
                                        </tr>
                                        <tr>
                                            <td width="207" style="width:155.35pt;border:solid windowtext 1.0pt;    border-top:none;padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top">
                                                <p style="line-height:normal" class="MsoNormal">
                                                    <span lang="NO-BOK">Hud- og   underhudssykdommer</span>
                                                </p>
                                            </td>
                                            <td width="206" style="width:2.15in;border-top:none;border-left:    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top">
                                                <p style="line-height:normal" class="MsoNormal">
                                                    <span lang="NO-BOK">Erytem</span>
                                                </p>
                                                <p style="line-height:normal" class="MsoNormal">
                                                    <span lang="NO-BOK">Flelse av   svie i huden</span>
                                                </p>
                                                <p style="line-height:normal" class="MsoNormal">
                                                    <span lang="NO-BOK">Kle</span>
                                                </p>
                                                <p style="line-height:normal" class="MsoNormal">
                                                    <span lang="NO-BOK">Allergisk   hudreaksjon</span>
                                                </p>
                                            </td>
                                            <td width="206" style="width:154.2pt;border-top:none;border-left:    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top">
                                                <p style="line-height:normal" class="MsoNormal">
                                                    <span lang="NO-BOK">Vanlige</span>
                                                </p>
                                                <p style="line-height:normal" class="MsoNormal">
                                                    <span lang="NO-BOK">Vanlige</span>
                                                </p>
                                                <p style="line-height:normal" class="MsoNormal">
                                                    <span lang="NO-BOK">Vanlige</span>
                                                </p>
                                                <p style="line-height:normal" class="MsoNormal">
                                                    <span lang="NO-BOK">Sjeldne</span>
                                                </p>
                                            </td>
                                        </tr>
                                        <tr>
                                            <td width="207" style="width:155.35pt;border:solid windowtext 1.0pt;    border-top:none;padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top">
                                                <p style="line-height:normal" class="MsoNormal">
                                                    <span lang="NO-BOK">Sykdommer i   nyre og urinveier</span>
                                                </p>
                                            </td>
                                            <td width="206" style="width:2.15in;border-top:none;border-left:    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top">
                                                <p style="line-height:normal" class="MsoNormal">
                                                    <span lang="NO-BOK">Proteinuri</span>
                                                </p>
                                                <p style="line-height:normal" class="MsoNormal">
                                                    <span lang="NO-BOK">Nyresvikt</span>
                                                </p>
                                                <p style="line-height:normal" class="MsoNormal">
                                                    <span lang="NO-BOK">Fanconi-syndrom*</span>
                                                </p>
                                            </td>
                                            <td width="206" style="width:154.2pt;border-top:none;border-left:    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top">
                                                <p style="line-height:normal" class="MsoNormal">
                                                    <span lang="NO-BOK">Mindre   vanlige</span>
                                                </p>
                                                <p style="line-height:normal" class="MsoNormal">
                                                    <span lang="NO-BOK">Ikke kjent</span>
                                                </p>
                                                <p style="line-height:normal" class="MsoNormal">
                                                    <span lang="NO-BOK">Ikke kjent</span>
                                                </p>
                                            </td>
                                        </tr>
                                        <tr>
                                            <td width="207" style="width:155.35pt;border:solid windowtext 1.0pt;    border-top:none;padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top">
                                                <p style="line-height:normal" class="MsoNormal">
                                                    <span lang="NO-BOK">Generelle   lidelser og reaksjoner p administrasjonsstedet </span>
                                                </p>
                                            </td>
                                            <td width="206" style="width:2.15in;border-top:none;border-left:    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top">
                                                <p style="line-height:normal" class="MsoNormal">
                                                    <span lang="NO-BOK">Tretthet</span>
                                                </p>
                                                <p style="line-height:normal" class="MsoNormal">
                                                    <span lang="NO-BOK">Varmeflelse</span>
                                                </p>
                                                <p style="line-height:normal" class="MsoNormal">
                                                    <span lang="NO-BOK">Asteni</span>
                                                </p>
                                            </td>
                                            <td width="206" style="width:154.2pt;border-top:none;border-left:    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top">
                                                <p style="line-height:normal" class="MsoNormal">
                                                    <span lang="NO-BOK">Vanlige</span>
                                                </p>
                                                <p style="line-height:normal" class="MsoNormal">
                                                    <span lang="NO-BOK">Vanlige</span>
                                                </p>
                                                <p style="line-height:normal" class="MsoNormal">
                                                    <span lang="NO-BOK">Vanlige</span>
                                                </p>
                                            </td>
                                        </tr>
                                        <tr>
                                            <td width="207" style="width:155.35pt;border:solid windowtext 1.0pt;    border-top:none;padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top">
                                                <p style="line-height:normal" class="MsoNormal">
                                                    <span lang="NO-BOK">Underskelser</span>
                                                </p>
                                            </td>
                                            <td width="206" style="width:2.15in;border-top:none;border-left:    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top">
                                                <p style="line-height:normal" class="MsoNormal">
                                                    <span lang="NO-BOK">kte   leverenzymer</span>
                                                </p>
                                                <p style="line-height:normal" class="MsoNormal">
                                                    <span lang="NO-BOK">kt   serumkreatinin</span>
                                                </p>
                                            </td>
                                            <td width="206" style="width:154.2pt;border-top:none;border-left:    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top">
                                                <p style="line-height:normal" class="MsoNormal">
                                                    <span lang="NO-BOK">Vanlige</span>
                                                </p>
                                                <p style="line-height:normal" class="MsoNormal">
                                                    <span lang="NO-BOK">Mindre   vanlige</span>
                                                </p>
                                            </td>
                                        </tr>
                                    </table>
                                    <p style="line-height:normal" class="MsoNormal">
                                        <span style="font-size:9.0pt" lang="NO-BOK">* Ytterligere bivirkninger rapportert med Fumaderm, et relatert legemiddel som inneholder dimetylfumarat samt andre fumarsyreestere.</span>
                                    </p>
                                    <p style="line-height:normal" class="MsoNormal">
                                        <span style="font-size:9.0pt" lang="NO-BOK">**Bivirkninger som ble rapportert  etter markedsfring.</span>
                                    </p>
                                    <p style="line-height:normal" class="MsoNormal"/>
                                    <p style="line-height:normal;page-break-after:avoid" class="MsoNormal">
                                        <u>
                                            <span lang="NO-BOK">Beskrivelse av utvalgte bivirkninger</span>
                                        </u>
                                    </p>
                                    <p style="line-height:normal;page-break-after:avoid" class="MsoNormal">
                                        <i>
                                            <span lang="NO-BOK">Gastrointestinale forstyrrelser</span>
                                        </i>
                                    </p>
                                    <p style="line-height:normal;page-break-after:avoid" class="MsoNormal">
                                        <span lang="NO-BOK">Data fra den kliniske fase III-studien samt fra litteratur viser at gastrointestinale sykdommer med dimetylfumaratholdige legemidler mest sannsynlig oppstr i lpet av de frste 2 til 3 mnedene etter at behandlingen er pbegynt. Ingen klar dosesammenheng  og ingen risikofaktorer for forekomst av disse bivirkningene kunne identifiseres. Diar var en vanlig bivirkning (36,9 %) blant pasienter som tok Acme Product, og dette frte til at legemidlet ble seponert hos omtrent 10 % av pasientene. Mer enn 9 % av disse diarhendelsene var av mild til moderat alvorlighetsgrad (se pkt. 4.4).</span>
                                    </p>
                                    <p style="line-height:normal" class="MsoNormal"/>
                                    <p style="line-height:normal;page-break-after:avoid" class="MsoNormal">
                                        <i>
                                            <span lang="NO-BOK">Rdme/flushing</span>
                                        </i>
                                    </p>
                                    <p style="line-height:normal;page-break-after:avoid" class="MsoNormal">
                                        <span lang="NO-BOK">Basert p observasjoner i den klinske fase III-studien samt litteraturdata oppstr rdme oftest i lpet av de frste ukene av behandlingen og har en tendens til  reduseres over tid. I den kliniske studien opplevde totalt 20,8 % av pasientene som fikk Acme Product rdme som var mild i de fleste tilfellene (se pkt. 4.4). Publisert klinisk erfaring med dimetylfumaratholdige legemidler viser at individuelle episoder med rdme vanligvis begynner kort tid etter inntak av tablettene og opphrer innen noen timer.</span>
                                    </p>
                                    <p style="line-height:normal" class="MsoNormal"/>
                                    <p style="line-height:normal;page-break-after:avoid" class="MsoNormal">
                                        <i>
                                            <span lang="NO-BOK">Hematologiske forandringer</span>
                                        </i>
                                    </p>
                                    <p style="line-height:normal;page-break-after:avoid" class="MsoNormal">
                                        <span lang="NO-BOK">Data fra den kliniske fase III-studien samt fra litteraturen viser
at forandringer i hematologiske parametere mest sannsynlig forekommer i lpet
av de frste 3 mnedene etter at behandlingen med dimetylfumarat er
pbegynt. Spesielt var det i den kliniske studien en lett reduksjon i
gjennomsnittlige lymfocyttniver som begynte mellom uke 3 og 5 og var
maksimal innen uke 12, der omtrent en tredjedel av pasientene hadde
lymfocyttverdier under 1,0 x 10
                                            <sup>9</sup>/l. Gjennomsnitts- og
medianverdiene for lymfocytter forble innenfor normalomrdet i lpet av den
kliniske studien. Ved uke 16 (behandlingsslutt) var det ingen ytterligere
reduksjon i lymfocyttallene. Ved uke 16 av behandlingen ble det vist at 13/175
(7,4 %) av pasientene hadde lymfocyttniver &lt;0,7 x 10
                                            <sup>9</sup>/l. Blodprvetaking
for kliniske sikkerhetslaboratorietester ved oppflgingsbeskene ble kun utfrt
i tilfelle uregelmessigheter ved forutgende besk. I lpet av den
behandlingsfrie oppflgingen ble det observert lymfocyttniver p &lt;0,7 x 10
                                            <sup>9</sup>/l
hos 1/29 (3,5 %) pasienter ved 6 mneder og 0/28 (0 %) ved 12 mneder
etter seponering av behandlingen. Ved 12 mneder etter seponering av
behandlingen hadde 3/28 (10,7 %) pasienter lymfocyttverdier under 1,0 x 10
                                            <sup>9</sup>/l,
og dette ville representere 3/279 (1,1 %) av pasientene som begynte p
Acme Product.
                                        </span>
                                    </p>
                                    <p style="line-height:normal" class="MsoNormal"/>
                                    <p style="line-height:normal" class="MsoNormal">
                                        <span lang="NO-BOK">For det totale
leukocyttallet ble en reduksjon vist ved uke 12 av behandlingen, det kte
langsomt igjen ved uke 16 (behandlingsslutt), og 12 mneder etter
seponering av behandlingen hadde alle pasienter verdier over 3,0 x 10
                                            <sup>9</sup>/l.
                                        </span>
                                    </p>
                                    <p style="line-height:normal" class="MsoNormal"/>
                                    <p style="line-height:normal" class="MsoNormal">
                                        <span lang="NO-BOK">En forbigende kning i gjennomsnittsverdier for eosinofiler ble observert s tidlig som uke 3, ndde maksimal verdi ved uke 5 og 8,og hadde returnert til baselineverdier ved uke 16.</span>
                                    </p>
                                    <p style="line-height:normal" class="MsoNormal"/>
                                    <p style="line-height:normal" class="MsoNormal">
                                        <span lang="NO-BOK">For overvkningsanbefalinger og klinisk hndtering av hematologiske bivirkninger, se pkt 4.4.</span>
                                    </p>
                                    <p style="line-height:normal" class="MsoNormal">
                                        <u>
                                            <span lang="NO-BOK"/>
                                        </u>
                                    </p>
                                </div>
              </text>
              <section id="267ecb50-3623-4dbe-8071-840f0ca2889b">
                <title value="Melding av mistenkte bivirkninger"/>
                <code>
                  <coding>
                    <system value="http://spor.ema.europa.eu/v1/example-sections"/>
                    <code value="29"/>
                    <display value="Melding av mistenkte bivirkninger"/>
                  </coding>
                </code>
                <text>
                  <status value="additional"/><div xmlns="http://www.w3.org/1999/xhtml">
                                        <p style="line-height:normal;page-break-after:avoid" class="MsoNormal">
                                            <span lang="NO-BOK">Melding av mistenkte bivirkninger etter godkjenning av legemidlet
er viktig. Det gjr det mulig  overvke forholdet mellom nytte og risiko for
legemidlet kontinuerlig. Helsepersonell oppfordres til  melde enhver mistenkt
bivirkning. Dette gjres 
                                                <span style="color:black">via 
                                                    <span style="background:  lightgrey">det nasjonale meldesystemet som beskrevet i </span>
                                                </span>
                                            </span>
                                            <span lang="EN-GB">
                                                <a href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc">
                                                    <span style="background:lightgrey">Appendix V</span>
                                                </a>
                                            </span>
                                            <span lang="NO-BOK">.</span>
                                        </p>
                                        <p style="line-height:normal;page-break-after:avoid" class="MsoNormal"/>
                                    </div>
                </text>
              </section>
            </section>
            <section id="68f3502a-0e58-4cab-a49a-e9c68496e1df">
              <title value="4.9     Overdosering"/>
              <code>
                <coding>
                  <system value="http://spor.ema.europa.eu/v1/example-sections"/>
                  <code value="30"/>
                  <display value="4.9 Overdosering"/>
                </coding>
              </code>
              <text>
                <status value="additional"/><div xmlns="http://www.w3.org/1999/xhtml">
                                    <p style="line-height:normal;page-break-after:avoid" class="MsoNormal"/>
                                    <p style="line-height:normal;page-break-after:avoid" class="MsoNormal">
                                        <span lang="NO-BOK">Symptomatisk behandling er indisert ved overdosering. Ingen spesifikk motgift er kjent.</span>
                                    </p>
                                    <p style="line-height:normal" class="MsoNormal"/>
                                    <p style="line-height:normal" class="MsoNormal"/>
                                </div>
              </text>
            </section>
          </section>
          <section id="bfaa811c-6b32-4216-be85-3cb156c82bb2">
            <title value="5.       FARMAKOLOGISKE EGENSKAPER"/>
            <code>
              <coding>
                <system value="http://spor.ema.europa.eu/v1/example-sections"/>
                <code value="32"/>
                <display value="5. FARMAKOLOGISKE EGENSKAPER"/>
              </coding>
            </code>
            <text>
              <status value="additional"/><div xmlns="http://www.w3.org/1999/xhtml">
                                <p style="line-height:normal;page-break-after:avoid" class="MsoNormal"/>
                            </div>
            </text>
            <section id="5f641461-bcca-46a8-8bfe-4838ebf7bf99">
              <title value="5.1     Farmakodynamiske egenskaper"/>
              <code>
                <coding>
                  <system value="http://spor.ema.europa.eu/v1/example-sections"/>
                  <code value="33"/>
                  <display value="5.1 Farmakodynamiske egenskaper"/>
                </coding>
              </code>
              <text>
                <status value="additional"/><div xmlns="http://www.w3.org/1999/xhtml">
                                    <p style="line-height:normal;page-break-after:avoid" class="MsoNormal"/>
                                    <p style="line-height:normal;page-break-after:avoid" class="MsoNormal">
                                        <span lang="NO-BOK">Farmakoteraputisk gruppe: Andre immunsuppressiver, ATC-kode: L04AX07</span>
                                    </p>
                                    <p style="line-height:normal" class="MsoNormal">
                                        <u>
                                            <span lang="NO-BOK"/>
                                        </u>
                                    </p>
                                </div>
              </text>
              <section id="5b40031c-aad3-4fc1-b495-9683f84496ec">
                <title value="Virkningsmekanisme"/>
                <code>
                  <coding>
                    <system value="http://spor.ema.europa.eu/v1/example-sections"/>
                    <code value="34"/>
                    <display value="Virkningsmekanisme"/>
                  </coding>
                </code>
                <text>
                  <status value="additional"/><div xmlns="http://www.w3.org/1999/xhtml">
                                        <p style="line-height:normal;page-break-after:avoid" class="MsoNormal">
                                            <span lang="NO-BOK">De antiinflammatoriske og immunmodulerende effektene av dimetylfumarat og dets metabolitt monometylfumarat er ikke fullt ut klarlagt, men antas hovedsakelig  vre grunnet interaksjon med intracellulrt redusert glutation i celler som er direkte involvert i patogenesen ved psoriasis. Denne interaksjonen med glutation frer til hemming av translokasjon inn i kjernen, og den transkripsjonelle aktiviteten til nukler faktor kappa-lettkjede-enhancer av aktiverte B-celler (NF-B). </span>
                                        </p>
                                        <p style="line-height:normal" class="MsoNormal"/>
                                        <p style="line-height:normal" class="MsoNormal">
                                            <span lang="NO-BOK">Den primre aktiviteten av dimetylfumarat og monometylfumarat anses  vre immunmodulerende, noe som resulterer i en endring av T-hjelperceller (Th) fra Th1- og Th17-profil til en Th2-fenotype. Inflammatorisk cytokinproduksjon reduseres ved induksjon av proapoptotiske hendelser, hemming av keratinocytt-proliferasjon, redusert uttrykk av adhesjonsmolekyler og redusert inflammatorisk infiltrat i psoriasisplakk. </span>
                                        </p>
                                        <p style="line-height:normal" class="MsoNormal">
                                            <u>
                                                <span lang="NO-BOK"/>
                                            </u>
                                        </p>
                                    </div>
                </text>
              </section>
              <section id="16cf40c8-e667-431a-a1b0-8dc621a4a1c3">
                <title value="Klinisk effekt og sikkerhet"/>
                <code>
                  <coding>
                    <system value="http://spor.ema.europa.eu/v1/example-sections"/>
                    <code value="36"/>
                    <display value="Klinisk effekt og sikkerhet"/>
                  </coding>
                </code>
                <text>
                  <status value="additional"/><div xmlns="http://www.w3.org/1999/xhtml">
                                        <p style="line-height:normal;page-break-after:avoid" class="MsoNormal">
                                            <span lang="NO-BOK">Sikkerhet og effekt av Acme Product ble underskt i en dobbeltblindet, 3-armet fase III-studie (1102) med placebo og aktiv komparator</span>
                                            <span lang="NO-BOK">kontroll</span>
                                            <span lang="NO-BOK">med pasienter med moderat til alvorlig plakkpsoriasis (studie 1102). I studien ble 704 pasienter  randomisert til Acme Product, en aktiv komparator (Fumaderm, et kombinasjonspreparat med samme innhold av dimetylfumarat pluss 3 monoetylfumaratsalter) og placebo i et forhold p 2:2:1. Pasienter begynte behandling med tabletter med innhold 30 mg/dag dimetylfumarat eller placebo, og titrering opp til maksimalt 720 mg/dag i begge aktive behandlingsarmer som beskrevet i pkt. 4.2. Dersom behandlingseffekt ble observert fr maksimaldosen p dimetylfumarat 720 mg/dag var ndd, var det undvendig med en ytterligere kning av dosen, og dosen skulle reduseres jevnt til en individuell vedlikeholdsdose. Ved individuell intolerabilitet ved kt dosering i lpet av uke 4 til 16, skulle pasienten g tilbake til den siste tolererte dosen tatt siden start av uke 4, og som skulle opprettholdes inntil slutten av behandlingsperioden (uke 16). Pasientene mottok behandling i opp til 16 uker og oppflgingsbesk var planlagt for opp til 12 mneder etter avsluttet behandling.</span>
                                        </p>
                                        <p style="line-height:normal" class="MsoNormal"/>
                                        <p style="line-height:normal" class="MsoNormal">
                                            <span lang="NO-BOK">Det var god balanse i demografiske og baselineparametre mellom behandlingsgruppene. Av de 699 pasientene var de fleste var kaukasiere (99 %) og menn (65 %), og gjennomsnittsalderen var 44 r. De fleste pasientene (91 %) var &lt;65 r. De fleste pasientene hadde moderat psoriasis basert p PASI-skr for psoriasisomrde og alvorlighetsgrad (Psoriasis Area and Severity Index) og PGAI-skr for legens totalvurdering (Physicians Global Assessment) ved baseline: gjennomsnittlig PASI-skr ved baseline var 16,35 og 60 % av pasientene ble scoret som moderat p PGA. Flertallet av pasientene rapporterte en &quot;svrt hy&quot; eller &quot;ekstremt hy&quot; pvirkning av psoriasis p sitt liv basert p Dermatologisk livskvalitetsindeks (DLQI), med en gjennomsnittlig DLQI-skr p 11,5. </span>
                                        </p>
                                        <p style="line-height:normal" class="MsoNormal"/>
                                        <p style="line-height:normal;text-autospace:none" class="MsoNormal">
                                            <span lang="NO-BOK">Etter 16 ukers behandling ble Acme Product funnet  vre bedre enn placebo (p &lt;0,0001) basert p PASI 75 og PGA-skr p helet eller nesten tilhelet, og ikke drligere (ved bruk av en non-inferioritymargin p 15 %) enn den aktive komparatoren (p &lt;0,0003) basert p PASI 75.</span>
                                        </p>
                                        <p style="line-height:normal" class="MsoNormal"/>
                                        <table border="0" cellpadding="0" cellspacing="0" width="612" style="border-collapse:collapse" class="MsoNormalTable">
                                            <tr>
                                                <td colspan="7" width="612" style="width:459.0pt;padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top">
                                                    <p style="line-height:normal;page-break-after:avoid" class="MsoNormal">
                                                        <b>
                                                            <span style="font-size:10.0pt" lang="NO-BOK">Oppsummering av klinisk effekt etter 16   ukers behandling i studie 1102</span>
                                                        </b>
                                                    </p>
                                                </td>
                                            </tr>
                                            <tr>
                                                <td width="272" style="width:203.85pt;border:none;border-top:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top">
                                                    <p style="line-height:normal;page-break-after:avoid" class="MsoNormal">
                                                        <b>
                                                            <span style="font-size:10.0pt" lang="NO-BOK">Vurdering</span>
                                                        </b>
                                                    </p>
                                                </td>
                                                <td colspan="2" width="123" style="width:92.15pt;border:none;    border-top:solid windowtext 1.0pt;padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top">
                                                    <p style="text-align:center;line-height:normal;    page-break-after:avoid" align="center" class="MsoNormal">
                                                        <b>
                                                            <span style="font-size:10.0pt" lang="EN-GB">Acme Product</span>
                                                        </b>
                                                    </p>
                                                </td>
                                                <td colspan="3" width="95" style="width:70.9pt;border:none;border-top:    solid windowtext 1.0pt;padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top">
                                                    <p style="text-align:center;line-height:normal;    page-break-after:avoid" align="center" class="MsoNormal">
                                                        <b>
                                                            <span style="font-size:10.0pt" lang="EN-GB">Placebo</span>
                                                        </b>
                                                    </p>
                                                </td>
                                                <td width="123" style="width:92.1pt;border:none;border-top:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top">
                                                    <p style="text-align:center;line-height:normal;    page-break-after:avoid" align="center" class="MsoNormal">
                                                        <b>
                                                            <span style="font-size:10.0pt" lang="EN-GB">Fumaderm</span>
                                                        </b>
                                                    </p>
                                                </td>
                                            </tr>
                                            <tr>
                                                <td width="272" style="width:203.85pt;border:none;border-bottom:    solid windowtext 1.0pt;padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top">
                                                    <p style="line-height:normal;page-break-after:avoid" class="MsoNormal"/>
                                                </td>
                                                <td colspan="2" width="123" style="width:92.15pt;border:none;    border-bottom:solid windowtext 1.0pt;padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top">
                                                    <p style="text-align:center;line-height:normal;    page-break-after:avoid" align="center" class="MsoNormal">
                                                        <b>
                                                            <span style="font-size:10.0pt" lang="EN-GB">N=267</span>
                                                        </b>
                                                    </p>
                                                </td>
                                                <td colspan="3" width="95" style="width:70.9pt;border:none;border-bottom:    solid windowtext 1.0pt;padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top">
                                                    <p style="text-align:center;line-height:normal;    page-break-after:avoid" align="center" class="MsoNormal">
                                                        <b>
                                                            <span style="font-size:10.0pt" lang="EN-GB">N=131</span>
                                                        </b>
                                                    </p>
                                                </td>
                                                <td width="123" style="width:92.1pt;border:none;border-bottom:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top">
                                                    <p style="text-align:center;line-height:normal;    page-break-after:avoid" align="center" class="MsoNormal">
                                                        <b>
                                                            <span style="font-size:10.0pt" lang="EN-GB">N=273</span>
                                                        </b>
                                                    </p>
                                                </td>
                                            </tr>
                                            <tr>
                                                <td colspan="7" width="612" style="width:459.0pt;border:none;    padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top">
                                                    <p style="line-height:normal;page-break-after:avoid" class="MsoNormal">
                                                        <b>
                                                            <span style="font-size:10.0pt" lang="NO-BOK">Superiority testing kontra placebo</span>
                                                        </b>
                                                    </p>
                                                </td>
                                            </tr>
                                            <tr>
                                                <td width="272" style="width:203.85pt;padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top">
                                                    <p style="text-align:justify;text-justify:inter-ideograph;    line-height:normal;page-break-after:avoid" class="MsoNormal">
                                                        <b>
                                                            <span style="font-size:10.0pt" lang="NO-BOK">PASI 75</span>
                                                        </b>
                                                        <span style="font-size:10.0pt" lang="NO-BOK">, n (%)</span>
                                                    </p>
                                                </td>
                                                <td colspan="2" width="123" style="width:92.15pt;padding:1.4pt 5.4pt 1.4pt 5.4pt">
                                                    <p style="text-align:center;line-height:normal;    page-break-after:avoid" align="center" class="MsoNormal">
                                                        <span style="font-size:10.0pt" lang="EN-GB">100 (37,5)</span>
                                                    </p>
                                                </td>
                                                <td colspan="3" width="95" style="width:70.9pt;padding:1.4pt 5.4pt 1.4pt 5.4pt">
                                                    <p style="text-align:center;line-height:normal;    page-break-after:avoid" align="center" class="MsoNormal">
                                                        <span style="font-size:10.0pt" lang="EN-GB">20 (15,3)</span>
                                                    </p>
                                                </td>
                                                <td width="123" style="width:92.1pt;padding:1.4pt 5.4pt 1.4pt 5.4pt">
                                                    <p style="text-align:center;line-height:normal;    page-break-after:avoid" align="center" class="MsoNormal">
                                                        <span style="font-size:10.0pt" lang="EN-GB">110 (40,3)</span>
                                                    </p>
                                                </td>
                                            </tr>
                                            <tr>
                                                <td width="272" style="width:203.85pt;padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top">
                                                    <p style="margin-left:7.1pt;line-height:normal;page-break-after:    avoid" class="MsoNormal">
                                                        <span style="font-size:10.0pt" lang="NO-BOK">p-verdi</span>
                                                    </p>
                                                </td>
                                                <td colspan="3" width="170" style="width:127.6pt;padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top">
                                                    <p style="margin-right:15.85pt;text-align:right;    line-height:normal" align="right" class="MsoNormal">
                                                        <span style="font-size:10.0pt" lang="EN-GB">&lt;0,0001
                                                            <sup>a</sup>
                                                        </span>
                                                    </p>
                                                </td>
                                                <td colspan="3" width="170" style="width:127.55pt;padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top">
                                                    <p style="margin-left:15.85pt;line-height:normal" class="MsoNormal">
                                                        <span style="font-size:10.0pt" lang="EN-GB">&lt;0,0001
                                                            <sup>a</sup>
                                                        </span>
                                                    </p>
                                                </td>
                                            </tr>
                                            <tr>
                                                <td width="272" style="width:203.85pt;padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top">
                                                    <p style="line-height:normal;page-break-after:avoid" class="MsoNormal">
                                                        <b>
                                                            <span style="font-size:10.0pt" lang="SV">Tosidig 99,24 % KI</span>
                                                        </b>
                                                    </p>
                                                </td>
                                                <td colspan="3" width="170" style="width:127.6pt;padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top">
                                                    <p style="margin-right:14.2pt;text-align:right;    line-height:normal;page-break-after:avoid" align="right" class="MsoNormal">
                                                        <span style="font-size:    10.0pt" lang="IT">10,7, 33,7
                                                            <sup>a</sup>
                                                        </span>
                                                    </p>
                                                </td>
                                                <td colspan="3" width="170" style="width:127.55pt;padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top">
                                                    <p style="margin-left:8.75pt;line-height:normal" class="MsoNormal">
                                                        <span style="font-size:10.0pt" lang="IT">13,5, 36,6</span>
                                                        <sup>
                                                            <span style="font-size:10.0pt" lang="EN-GB">a</span>
                                                        </sup>
                                                    </p>
                                                </td>
                                            </tr>
                                            <tr>
                                                <td width="272" style="width:203.85pt;padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top">
                                                    <p style="line-height:normal;page-break-after:avoid" class="MsoNormal">
                                                        <b>
                                                            <span style="font-size:10.0pt" lang="NO-BOK">PGA-skr helet eller nesten helet,</span>
                                                        </b>
                                                        <span style="font-size:10.0pt" lang="NO-BOK">n (%)</span>
                                                    </p>
                                                </td>
                                                <td colspan="2" width="123" style="width:92.15pt;padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top">
                                                    <p style="text-align:center;line-height:normal;    page-break-after:avoid" align="center" class="MsoNormal">
                                                        <span style="font-size:10.0pt" lang="EN-GB">88 (33,0)</span>
                                                    </p>
                                                </td>
                                                <td colspan="3" width="95" style="width:70.9pt;padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top">
                                                    <p style="text-align:center;line-height:normal;    page-break-after:avoid" align="center" class="MsoNormal">
                                                        <span style="font-size:10.0pt" lang="EN-GB">17 (13,0)</span>
                                                    </p>
                                                </td>
                                                <td width="123" style="width:92.1pt;padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top">
                                                    <p style="text-align:center;line-height:normal;    page-break-after:avoid" align="center" class="MsoNormal">
                                                        <span style="font-size:10.0pt" lang="EN-GB">102 (37,4)</span>
                                                    </p>
                                                </td>
                                            </tr>
                                            <tr>
                                                <td width="272" style="width:203.85pt;padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top">
                                                    <p style="margin-left:7.1pt;line-height:normal;page-break-after:    avoid" class="MsoNormal">
                                                        <span style="font-size:10.0pt" lang="NO-BOK">p-verdi</span>
                                                    </p>
                                                </td>
                                                <td colspan="3" width="170" style="width:127.6pt;padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top">
                                                    <p style="margin-right:15.85pt;text-align:right;    line-height:normal" align="right" class="MsoNormal">
                                                        <span style="font-size:10.0pt" lang="EN-GB">&lt;0,0001
                                                            <sup>a</sup>
                                                        </span>
                                                    </p>
                                                </td>
                                                <td colspan="3" width="170" style="width:127.55pt;padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top">
                                                    <p style="margin-left:15.85pt;line-height:normal" class="MsoNormal">
                                                        <span style="font-size:10.0pt" lang="EN-GB">&lt;0,0001
                                                            <sup>a</sup>
                                                        </span>
                                                    </p>
                                                </td>
                                            </tr>
                                            <tr>
                                                <td width="272" style="width:203.85pt;border:none;border-bottom:    solid windowtext 1.0pt;padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top">
                                                    <p style="margin-left:7.1pt;line-height:normal;page-break-after:    avoid" class="MsoNormal">
                                                        <span style="font-size:10.0pt" lang="EN-GB">Tosidig 99.24%KI</span>
                                                    </p>
                                                </td>
                                                <td colspan="3" width="170" style="width:127.6pt;border:none;    border-bottom:solid windowtext 1.0pt;padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top">
                                                    <p style="margin-right:14.2pt;text-align:right;    line-height:normal;page-break-after:avoid" align="right" class="MsoNormal">
                                                        <span style="font-size:    10.0pt" lang="EN-GB">9,0, 31,0
                                                            <sup>a</sup>
                                                        </span>
                                                    </p>
                                                </td>
                                                <td colspan="3" width="170" style="width:127.55pt;border:none;    border-bottom:solid windowtext 1.0pt;padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top">
                                                    <p style="margin-left:8.75pt;line-height:normal" class="MsoNormal">
                                                        <span style="font-size:10.0pt" lang="EN-GB">13,3, 35,5
                                                            <sup>a</sup>
                                                        </span>
                                                    </p>
                                                </td>
                                            </tr>
                                            <tr>
                                                <td colspan="2" width="319" style="width:239.3pt;padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top">
                                                    <p style="line-height:normal;page-break-after:avoid" class="MsoNormal"/>
                                                </td>
                                                <td colspan="3" width="142" style="width:106.3pt;padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top">
                                                    <p style="text-align:center;line-height:normal;    page-break-after:avoid" align="center" class="MsoNormal">
                                                        <b>
                                                            <span style="font-size:10.0pt" lang="EN-GB">Acme Product</span>
                                                        </b>
                                                    </p>
                                                </td>
                                                <td colspan="2" width="151" style="width:113.4pt;padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top">
                                                    <p style="text-align:center;line-height:normal;    page-break-after:avoid" align="center" class="MsoNormal">
                                                        <b>
                                                            <span style="font-size:10.0pt" lang="EN-GB">Fumaderm</span>
                                                        </b>
                                                    </p>
                                                </td>
                                            </tr>
                                            <tr>
                                                <td colspan="2" width="319" style="width:239.3pt;border:none;    border-bottom:solid windowtext 1.0pt;padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top">
                                                    <p style="line-height:normal;page-break-after:avoid" class="MsoNormal"/>
                                                </td>
                                                <td colspan="3" width="142" style="width:106.3pt;border:none;    border-bottom:solid windowtext 1.0pt;padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top">
                                                    <p style="text-align:center;line-height:normal;    page-break-after:avoid" align="center" class="MsoNormal">
                                                        <b>
                                                            <span style="font-size:10.0pt" lang="EN-GB">N=267</span>
                                                        </b>
                                                    </p>
                                                </td>
                                                <td colspan="2" width="151" style="width:113.4pt;border:none;    border-bottom:solid windowtext 1.0pt;padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top">
                                                    <p style="text-align:center;line-height:normal;    page-break-after:avoid" align="center" class="MsoNormal">
                                                        <b>
                                                            <span style="font-size:10.0pt" lang="EN-GB">N=273</span>
                                                        </b>
                                                    </p>
                                                </td>
                                            </tr>
                                            <tr>
                                                <td colspan="2" width="319" style="width:239.3pt;border:none;    padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top">
                                                    <p style="margin-left:7.1pt;line-height:normal;page-break-after:    avoid" class="MsoNormal">
                                                        <b>
                                                            <span style="font-size:10.0pt" lang="EN-GB">Non-inferiority av   Acme Product kontra Fumaderm</span>
                                                        </b>
                                                    </p>
                                                </td>
                                                <td colspan="3" width="142" style="width:106.3pt;border:none;    padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top">
                                                    <p style="text-align:center;line-height:normal;    page-break-after:avoid" align="center" class="MsoNormal"/>
                                                </td>
                                                <td colspan="2" width="151" style="width:113.4pt;border:none;padding:1.4pt 5.4pt 1.4pt 5.4pt">
                                                    <p style="text-align:center;line-height:normal;    page-break-after:avoid" align="center" class="MsoNormal"/>
                                                </td>
                                            </tr>
                                            <tr>
                                                <td colspan="2" width="319" style="width:239.3pt;padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top">
                                                    <p style="margin-left:7.1pt;line-height:normal;page-break-after:    avoid" class="MsoNormal">
                                                        <b>
                                                            <span style="font-size:10.0pt" lang="EN-GB">PASI 75</span>
                                                        </b>
                                                        <span style="font-size:10.0pt" lang="EN-GB">, n (%)</span>
                                                    </p>
                                                </td>
                                                <td colspan="3" width="142" style="width:106.3pt;padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top">
                                                    <p style="text-align:center;line-height:normal;    page-break-after:avoid" align="center" class="MsoNormal">
                                                        <span style="font-size:10.0pt" lang="EN-GB">100 (37,5)</span>
                                                    </p>
                                                </td>
                                                <td colspan="2" width="151" style="width:113.4pt;padding:1.4pt 5.4pt 1.4pt 5.4pt">
                                                    <p style="text-align:center;line-height:normal;    page-break-after:avoid" align="center" class="MsoNormal">
                                                        <span style="font-size:10.0pt" lang="EN-GB">110 (40,3)</span>
                                                    </p>
                                                </td>
                                            </tr>
                                            <tr>
                                                <td colspan="2" width="319" style="width:239.3pt;padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top">
                                                    <p style="margin-left:7.1pt;line-height:normal;page-break-after:    avoid" class="MsoNormal">
                                                        <span style="font-size:10.0pt" lang="EN-GB">p-verdi</span>
                                                    </p>
                                                </td>
                                                <td colspan="5" width="293" style="width:219.7pt;padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top">
                                                    <p style="text-align:center;line-height:normal;    page-break-after:avoid" align="center" class="MsoNormal">
                                                        <span style="font-size:10.0pt" lang="EN-GB">0,0003
                                                            <sup>b</sup>
                                                        </span>
                                                    </p>
                                                </td>
                                            </tr>
                                            <tr>
                                                <td colspan="2" width="319" style="width:239.3pt;padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top">
                                                    <p style="margin-left:7.1pt;line-height:normal;page-break-after:    avoid" class="MsoNormal">
                                                        <span style="font-size:10.0pt" lang="NO-BOK">Ensidig 97,5 % gjentatt KI   (nedre grense)</span>
                                                    </p>
                                                </td>
                                                <td colspan="5" width="293" style="width:219.7pt;padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top">
                                                    <p style="text-align:center;line-height:normal;    page-break-after:avoid" align="center" class="MsoNormal">
                                                        <span style="font-size:10.0pt" lang="EN-GB">-11,6
                                                            <sup>b</sup>
                                                        </span>
                                                    </p>
                                                </td>
                                            </tr>
                                            <tr>
                                                <td colspan="2" width="319" style="width:239.3pt;padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top">
                                                    <p style="margin-left:7.1pt;line-height:normal;page-break-after:    avoid" class="MsoNormal">
                                                        <b>
                                                            <span style="font-size:10.0pt" lang="NO-BOK">PGA-skr helet eller   nesten helet </span>
                                                        </b>
                                                        <span style="font-size:10.0pt" lang="NO-BOK">n (%)</span>
                                                    </p>
                                                </td>
                                                <td colspan="3" width="142" style="width:106.3pt;padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top">
                                                    <p style="text-align:center;line-height:normal;    page-break-after:avoid" align="center" class="MsoNormal">
                                                        <span style="font-size:10.0pt" lang="EN-GB">88 (33,0)</span>
                                                    </p>
                                                </td>
                                                <td colspan="2" width="151" style="width:113.4pt;padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top">
                                                    <p style="text-align:center;line-height:normal;    page-break-after:avoid" align="center" class="MsoNormal">
                                                        <span style="font-size:10.0pt" lang="EN-GB">102 (37,4)</span>
                                                    </p>
                                                </td>
                                            </tr>
                                            <tr>
                                                <td colspan="2" width="319" style="width:239.3pt;padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top">
                                                    <p style="margin-left:7.1pt;line-height:normal;page-break-after:    avoid" class="MsoNormal">
                                                        <span style="font-size:10.0pt" lang="EN-GB">p-verdi</span>
                                                    </p>
                                                </td>
                                                <td colspan="5" width="293" style="width:219.7pt;padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top">
                                                    <p style="text-align:center;line-height:normal;    page-break-after:avoid" align="center" class="MsoNormal">
                                                        <span style="font-size:10.0pt" lang="EN-GB">0,0007
                                                            <sup>b</sup>
                                                        </span>
                                                    </p>
                                                </td>
                                            </tr>
                                            <tr>
                                                <td colspan="2" width="319" style="width:239.3pt;border:none;    border-bottom:solid windowtext 1.0pt;padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top">
                                                    <p style="margin-left:7.1pt;line-height:normal;page-break-after:    avoid" class="MsoNormal">
                                                        <span style="font-size:10.0pt" lang="NO-BOK">Ensidig 97,5 % gjentatt KI   (nedre grense)</span>
                                                    </p>
                                                </td>
                                                <td colspan="5" width="293" style="width:219.7pt;border:none;    border-bottom:solid windowtext 1.0pt;padding:1.4pt 5.4pt 1.4pt 5.4pt" valign="top">
                                                    <p style="text-align:center;line-height:normal;    page-break-after:avoid" align="center" class="MsoNormal">
                                                        <span style="font-size:10.0pt" lang="EN-GB">13,0
                                                            <sup>b</sup>
                                                        </span>
                                                    </p>
                                                </td>
                                            </tr>
                                            <tr>
                                                <td colspan="7" width="612" style="width:459.0pt;border:none;    padding:0in 5.4pt 0in 5.4pt" valign="top">
                                                    <p style="line-height:normal" class="MsoNormal">
                                                        <span style="font-size:9.0pt" lang="NO-BOK">Fumaderm = Aktiv komparator = et kombinasjonspreparat   med samme innhold av dimetylfumarat pluss 3 monoetylhydrogenfumaratsalter;</span>
                                                        <span style="font-size:9.0pt" lang="NO-BOK">n </span>
                                                        <span style="font-size:9.0pt" lang="NO-BOK">= </span>
                                                        <span style="font-size:    9.0pt" lang="NO-BOK">antall pasienter med tilgjengelige data</span>
                                                        <span style="font-size:9.0pt" lang="NO-BOK">;</span>
                                                        <span style="font-size:9.0pt" lang="NO-BOK">N </span>
                                                        <span style="font-size:9.0pt" lang="NO-BOK">= </span>
                                                        <span style="font-size:9.0pt" lang="NO-BOK">antall </span>
                                                        <span style="font-size:9.0pt" lang="NO-BOK">pasienter</span>
                                                        <span style="font-size:    9.0pt" lang="NO-BOK">i </span>
                                                        <span style="font-size:9.0pt" lang="NO-BOK">populasjon</span>
                                                        <span style="font-size:9.0pt" lang="NO-BOK">; PASI </span>
                                                        <span style="font-size:9.0pt" lang="NO-BOK">= </span>
                                                        <span style="font-size:    9.0pt" lang="NO-BOK">Psoriasis Area Severity Index</span>
                                                        <span style="font-size:9.0pt" lang="NO-BOK">;</span>
                                                        <span style="font-size:9.0pt" lang="NO-BOK">PGA </span>
                                                        <span style="font-size:9.0pt" lang="NO-BOK">= </span>
                                                        <span style="font-size:9.0pt" lang="NO-BOK">Physicians Global Assessment</span>
                                                        <span style="font-size:9.0pt" lang="NO-BOK">; 
                                                            <sup>a</sup>Overlegenhet for
Acme Product kontra placebo med en differanse p 22,2 % for PASI 75 og 20,0 %
for PGA-skr helet eller nesten helet, overlegenhet av Fumaderm kontra
placebo med en differanse p 25,0 % for PASI og 24,4 % for PGA-skr helet eller
nesten helet.
                                                            <sup>b</sup>Non-inferiority  av Acme Product kontra Fumaderm med
en differanse p -2,8 % for PASI 75 og -4,4 % for PGA-skr helet eller nesten
helet.
                                                        </span>
                                                    </p>
                                                </td>
                                            </tr>
                                            <tr height="0">
                                                <td width="272" style="border:none"/>
                                                <td width="47" style="border:none"/>
                                                <td width="76" style="border:none"/>
                                                <td width="47" style="border:none"/>
                                                <td width="19" style="border:none"/>
                                                <td width="28" style="border:none"/>
                                                <td width="123" style="border:none"/>
                                            </tr>
                                        </table>
                                        <p style="line-height:normal;text-autospace:none" class="MsoNormal"/>
                                        <p style="line-height:normal;text-autospace:none" class="MsoNormal">
                                            <span lang="NO-BOK">Det var en trend i effektendepunktet PASI-skr gjennomsnittlig -% endring fra baseline, som indikerte begynnelsen av klinisk respons p Acme Product s tidlig som uke 3 (-11,8 %) som ble statistisk signifikant sammenlignet med placebo innen uke 8 (-30,9 %). Ytterligere forbedring ble sett innen uke 16 (-50,8 %).</span>
                                        </p>
                                        <p style="line-height:normal" class="MsoNormal">
                                            <a name="_Ref431313822"/>
                                        </p>
                                        <p style="line-height:normal" class="MsoNormal">
                                            <span lang="NO-BOK">Fordelene ved behandling med Acme Product ble ogs stttet av pasientenes selvopplevde forbedringer i livskvaliteten. I uke 16 hadde pasienter som ble behandlet med Acme Product en lavere gjennomsnittlig DLQI sammenlignet med placebo (5,4 kontra 8,8). </span>
                                        </p>
                                        <p style="line-height:normal" class="MsoNormal"/>
                                        <p style="line-height:normal" class="MsoNormal">
                                            <span lang="NO-BOK">Tilbakefall (definert som forverring p &gt;125 % av baseline PASI-verdi) ble vurdert etter 2 mneder uten behandling og viste seg  ikke vre et klinisk problem med fumarsyreestere, da det ble dokumentert hos svrt f pasienter (Acme Product 1,1 % og aktiv komparator 2,2 %, sammenlignet med 9,3 % i placebogruppen).</span>
                                        </p>
                                        <p style="line-height:normal" class="MsoNormal"/>
                                        <p style="line-height:normal" class="MsoNormal">
                                            <span lang="NO-BOK">Langsiktige effektdata er for tiden ikke tilgjengelige for Acme Product, men i farmakokinetiske og kliniske studier viste systemisk eksponering, effekt og sikkerhet seg  vre sammenlignbare for Acme Product og den aktive komparatoren som inneholder dimetylfumarat. Dermed er det rimelig  forvente at langsiktig effekt ogs er sammenlignbar for Acme Product og dimetylfumaratholdige legemidler. Opprettholdelse av langsiktig effekt har blitt godt beskrevet for andre dimetylfumaratholdige legemidler, og derfor kan det forventes at behandlingsfordelene som ses med Acme Product ved uke 16, opprettholdes hos pasienter som behandles p lang sikt, i minst 24 mneder.</span>
                                        </p>
                                        <p style="line-height:normal" class="MsoNormal"/>
                                    </div>
                </text>
              </section>
              <section id="b54479b6-e871-407c-af15-0aba326b4513">
                <title value="Pediatrisk populasjon"/>
                <code>
                  <coding>
                    <system value="http://spor.ema.europa.eu/v1/example-sections"/>
                    <code value="37"/>
                    <display value="Pediatrisk populasjon"/>
                  </coding>
                </code>
                <text>
                  <status value="additional"/><div xmlns="http://www.w3.org/1999/xhtml">
                                        <p style="line-height:normal;page-break-after:avoid" class="MsoNormal">
                                            <span lang="NO-BOK">Det europeiske legemiddelkontoret har gitt unntak fra forpliktelsen til  presentere resultater fra studier med Acme Product i alle undergrupper av den pediatriske populasjonen ved denne indikasjonen (se pkt. 4.2 for informasjon om pediatrisk bruk).</span>
                                        </p>
                                        <p style="line-height:normal" class="MsoNormal"/>
                                    </div>
                </text>
              </section>
            </section>
            <section id="a41f9de8-182e-456c-b2ef-e1d03a91da29">
              <title value="5.2     Farmakokinetiske egenskaper"/>
              <code>
                <coding>
                  <system value="http://spor.ema.europa.eu/v1/example-sections"/>
                  <code value="38"/>
                  <display value="5.2 Farmakokinetiske egenskaper"/>
                </coding>
              </code>
              <text>
                <status value="additional"/><div xmlns="http://www.w3.org/1999/xhtml">
                                    <p style="line-height:normal;page-break-after:avoid" class="MsoNormal">
                                        <u>
                                            <span lang="NO-BOK"/>
                                        </u>
                                    </p>
                                </div>
              </text>
              <section id="59ed6059-97ef-4228-b72b-7167ecbe8213">
                <title value="Absorpsjon"/>
                <code>
                  <coding>
                    <system value="http://spor.ema.europa.eu/v1/example-sections"/>
                    <code value="39"/>
                    <display value="Absorpsjon"/>
                  </coding>
                </code>
                <text>
                  <status value="additional"/><div xmlns="http://www.w3.org/1999/xhtml">
                                        <p style="line-height:normal" class="MsoNormal">
                                            <span lang="NO-BOK">Etter oral administrasjon pvises ikke dimetylfumarat i plasma fordi det raskt hydrolyseres av esteraser til sin aktive metabolitt monometylfumarat. Etter oral administrering av en enkelt tablett Acme Product p 120 mg til friske forskspersoner, ndde monometylfumarat maksimal plasmakonsentrasjoner p rundt 1325 ng/ml og 1311 ng/ml etter henholdsvis faste og matinntak. Nr Acme Product tas sammen med mat </span>
                                            <span lang="NO-BOK">forsinkes</span>
                                            <span lang="NO-BOK">t
                                                <sub>max</sub>for monometylfumarat fra 3,5 til 9,0 timer.
                                            </span>
                                        </p>
                                        <p style="line-height:normal" class="MsoNormal"/>
                                    </div>
                </text>
              </section>
              <section id="a2dd0a8f-9f20-425e-baa7-3d807b818e6b">
                <title value="Distribusjon"/>
                <code>
                  <coding>
                    <system value="http://spor.ema.europa.eu/v1/example-sections"/>
                    <code value="40"/>
                    <display value="Distribusjon"/>
                  </coding>
                </code>
                <text>
                  <status value="additional"/><div xmlns="http://www.w3.org/1999/xhtml">
                                        <p style="line-height:normal;page-break-after:avoid" class="MsoNormal">
                                            <span lang="NO-BOK">Plasmaproteinbindingen av monometylfumarat er omkring 50 %. Dimetylfumarat viser ikke noen bindingsaffinitet til serumproteiner som ytterligere kan bidra til dets hurtige eliminasjon fra sirkulasjonen. </span>
                                        </p>
                                        <p style="line-height:normal" class="MsoNormal"/>
                                    </div>
                </text>
              </section>
              <section id="564cb153-58a2-49ee-a6e2-bd5a5a9ae05f">
                <title value="Biotransformasjon"/>
                <code>
                  <coding>
                    <system value="http://spor.ema.europa.eu/v1/example-sections"/>
                    <code value="41"/>
                    <display value="Biotransformasjon"/>
                  </coding>
                </code>
                <text>
                  <status value="additional"/><div xmlns="http://www.w3.org/1999/xhtml">
                                        <p style="line-height:normal;page-break-after:avoid" class="MsoNormal">
                                            <span lang="NO-BOK">Biotransformasjonen av dimetylfumarat involverer ikke cytokrom
P450-isoenzymer. 
                                                <i>In vitro</i>-studier har vist at monometylfumarat ved
terapeutisk dose ikke hemmer eller induserer noen av cytokrom P450-enzymene,
den er ikke et substrat eller hemmer av P-glykoprotein og er ikke en hemmer av
de mest vanlige effluks- og opptakstransportrene.
                                                <i>In vitro</i>-studier har
vist at dimetylfumarat ved en terapeutisk dose ikke hemmer CYP3A4/5 og BCRP og
er en svak P-glykoproteininibitor.
                                            </span>
                                        </p>
                                        <p style="line-height:normal" class="MsoNormal"/>
                                        <p style="line-height:normal" id="7fa270b4-18aa-4b54-961c-e77d0a6b05b8" class="MsoNormal"/>
                                        <i>
                                            <span lang="NO-BOK">In vitro</span>
                                        </i>
                                        <none/>
                                        <p style="line-height:normal" id="7fa270b4-18aa-4b54-961c-e77d0a6b05b8" class="MsoNormal">
                                            <span lang="NO-BOK">-studier har vist at hydrolyse av dimetylfumarat til monometylfumarat skjer raskt ved pH8 (pH i tynntarmen), men ikke ved pH1 (pH i magesekken). En del av det totale dimetylfumaratet blir hydrolysert av esteraser og tynntarmens alkaliske milj, mens resten kommer inn i portveneblodet. Videre studier har vist at dimetylfumarat (og i mindre grad monometylfumarat) reagerer delvis med redusert glutation som danner en glutationforbindelse. Disse forbindelsene ble pvist i dyrestudier i tarmslimhinner hos rotter og i mindre grad i portveneblod. Ukonjugert dimetylfumarat kan imidlertid ikke pvises i plasma hos dyr eller psoriasispasienter etter oral administrering. Derimot kan ukonjugert monometylfumarat pvises i plasma. Videre metabolisme skjer ved oksideringen via trikarboksylsyresyklusen, som danner karbondioksid og vann. </span>
                                        </p>
                                        <p style="margin-right:-.1pt;line-height:normal" class="MsoNormal">
                                            <u>
                                                <span lang="NO-BOK"/>
                                            </u>
                                        </p>
                                    </div>
                </text>
              </section>
              <section id="ecca1616-154d-4478-91e8-cf9be6418312">
                <title value="Eliminasjon"/>
                <code>
                  <coding>
                    <system value="http://spor.ema.europa.eu/v1/example-sections"/>
                    <code value="42"/>
                    <display value="Eliminasjon"/>
                  </coding>
                </code>
                <text>
                  <status value="additional"/><div xmlns="http://www.w3.org/1999/xhtml">
                                        <p style="line-height:normal;page-break-after:avoid" class="MsoNormal">
                                            <span lang="NO-BOK">Utnding av CO
                                                <sub>2</sub>som flge av monometylfumaratets
metabolisme er den primre eliminasjonsveien. Bare sm mengder intakt
monometylfumarat skilles ut gjennom urin eller avfring. Den delen av
dimetylfumaratet som reagerer med glutation, med dannelse av en
glutationforbindelse, metaboliseres videre til merkaptopurinsyre, som utskilles
i urinen.
                                            </span>
                                        </p>
                                        <p style="line-height:normal" class="MsoNormal"/>
                                        <p style="line-height:normal" class="MsoNormal">
                                            <span lang="NO-BOK">Den tilsynelatende terminale eliminasjonshalveringstiden for monometylfumaratet er omtrent 2 timer.</span>
                                        </p>
                                        <p style="line-height:normal" class="MsoNormal"/>
                                    </div>
                </text>
              </section>
              <section id="91f77a7f-6acc-4ef9-8796-7d1e20bd8325">
                <title value="Linearitet/ikke-linearitet"/>
                <code>
                  <coding>
                    <system value="http://spor.ema.europa.eu/v1/example-sections"/>
                    <code value="43"/>
                    <display value="Linearitet/ikke-linearitet"/>
                  </coding>
                </code>
                <text>
                  <status value="additional"/><div xmlns="http://www.w3.org/1999/xhtml">
                                        <p style="line-height:normal;page-break-after:avoid" class="MsoNormal">
                                            <span lang="NO-BOK">Til tross for hy variasjon mellom pasienter, var eksponeringen
mlt som AUC og C
                                                <sub>max</sub>, generelt doseproporsjonal etter administrering
av enkeltdoser p 4 x 30 mg dimetylfumarat tabletter (total dose p 120 mg)
og 2 x 120 mg dimetylfumarat tabletter (total dose p 240 mg).
                                            </span>
                                        </p>
                                        <p style="line-height:normal" class="MsoNormal">
                                            <u>
                                                <span lang="NO-BOK"/>
                                            </u>
                                        </p>
                                        <p style="line-height:normal;page-break-after:avoid" class="MsoNormal">
                                            <u>
                                                <span lang="NO-BOK">Nedsatt nyrefunksjon</span>
                                            </u>
                                        </p>
                                        <p style="line-height:normal;page-break-after:avoid" class="MsoNormal">
                                            <span lang="NO-BOK">Ingen spesifikke studier har blitt utfrt hos pasienter med nedsatt nyrefunksjon. Men fordi eliminasjon via nyrene spiller en mindre rolle for totalclearance fra plasma, er det usannsynlig at nedsatt nyrefunksjon kan pvirke de farmakokinetiske egenskapene til Acme Product (se pkt. 4.2). </span>
                                        </p>
                                        <p style="line-height:normal" class="MsoNormal"/>
                                        <p style="line-height:normal;page-break-after:avoid" class="MsoNormal">
                                            <u>
                                                <span lang="NO-BOK">Nedsatt leverfunksjon</span>
                                            </u>
                                        </p>
                                        <p style="line-height:normal;page-break-after:avoid" class="MsoNormal">
                                            <span lang="NO-BOK">Ingen spesifikke studier har blitt utfrt hos pasienter med nedsatt leverfunksjon. Men ettersom dimetylfumarat metaboliseres av esteraser og det alkaliske miljet i tynntarmen uten at cytokrom P450 er involvert, forventes det ikke at nedsatt leverfunksjon pvirker eksponering (se pkt. 4.2). </span>
                                        </p>
                                        <p style="margin-right:-.1pt;line-height:normal" class="MsoNormal"/>
                                    </div>
                </text>
              </section>
            </section>
            <section id="c83d8044-45f8-43dc-b493-e9f29a019451">
              <title value="5.3     Prekliniske sikkerhetsdata"/>
              <code>
                <coding>
                  <system value="http://spor.ema.europa.eu/v1/example-sections"/>
                  <code value="45"/>
                  <display value="5.3 Prekliniske sikkerhetsdata"/>
                </coding>
              </code>
              <text>
                <status value="additional"/><div xmlns="http://www.w3.org/1999/xhtml">
                                    <p style="line-height:normal;page-break-after:avoid" class="MsoNormal"/>
                                    <p style="line-height:normal;page-break-after:avoid" class="MsoNormal">
                                        <span lang="NO-BOK">Prekliniske sikkerhetsfarmakologi- og gentoksisitetsdata indikerer ingen spesiell fare for mennesker.</span>
                                    </p>
                                    <p style="line-height:normal" class="MsoNormal"/>
                                    <p style="line-height:normal;page-break-after:avoid" class="MsoNormal">
                                        <u>
                                            <span lang="NO-BOK">Toksikologi</span>
                                        </u>
                                    </p>
                                    <p style="line-height:normal;page-break-after:avoid" class="MsoNormal">
                                        <span lang="NO-BOK">Nyrene ble identifisert som et viktig mlorgan for toksisitet i
prekliniske studier. Nyrefunn hos hunder omfattet minimal til moderat tubulr hypertrofi,
kt forekomst og alvorlighetsgrad av tubulr vakuolisering og minimal til liten
degenerering av nyretubuli, og dette ble ansett som toksikologisk relevant. Hyeste
niv uten observerte bivirkninger (NOAEL, noobserved
adverse-effect-level) etter 3 mneders behandling var 30 mg/kg/dag, noe
som tilsvarer 2,9 ganger og 9,5 ganger human systemisk eksponering
ved hyeste anbefalte dose (720 mg/dag), for henholdsvis AUC- og C
                                            <sub>max</sub>-verdier.
                                        </span>
                                    </p>
                                    <p style="line-height:normal" class="MsoNormal"/>
                                    <p style="line-height:normal;page-break-after:avoid" class="MsoNormal">
                                        <u>
                                            <span lang="NO-BOK">Reproduksjonstoksisitet </span>
                                        </u>
                                    </p>
                                    <p style="line-height:normal;page-break-after:avoid" class="MsoNormal">
                                        <span lang="NO-BOK">Ingen studier av fertilitet eller pre- og postnatal utvikling er blitt utfrt med Acme Product.</span>
                                    </p>
                                    <p style="line-height:normal" class="MsoNormal"/>
                                    <p style="line-height:normal" class="MsoNormal">
                                        <span lang="NO-BOK">Det var ingen
effekt p fostervekt eller misdannelser som kunne knyttes til maternelt inntak
av dimetylfumarat under studien av embryoftal utvikling hos rotter. Imidlertid
var det en kning i antall fostre med avvikene &quot;ekstra leverlapp&quot; og
&quot;unormal hoftekamjustering&quot; med maternelt toksiske doser. NOAEL for
maternell og embryoftal toksisitet var 40 mg/kg/dag, som tilsvarer 0,2 ganger
og 2,0 ganger human systemisk eksponering ved hyeste anbefalte dose
(720 mg/dag), for henholdsvis AUC- og C
                                            <sub>max</sub>-verdier.
                                        </span>
                                    </p>
                                    <p style="line-height:normal" class="MsoNormal"/>
                                    <p style="line-height:normal" class="MsoNormal">
                                        <span lang="NO-BOK">Det er vist at dimetylfumarat passerer placentamembranen til ftalt blod hos rotter.</span>
                                    </p>
                                    <p style="line-height:normal" class="MsoNormal"/>
                                    <p style="line-height:normal;page-break-after:avoid" class="MsoNormal">
                                        <u>
                                            <span lang="NO-BOK">Karsinogenisitet</span>
                                        </u>
                                    </p>
                                    <p style="line-height:normal;page-break-after:avoid" class="MsoNormal">
                                        <span lang="NO-BOK">Ingen karsinogenisitetsstudier er utfrt for Acme Product. Basert p tilgjengelige data som indikerer at fumarsyreestere kan aktivere cellulre mekanismer relatert til utvikling av nyretumorer, kan en potensiell tumorigen aktivitet av eksogent administrert dimetylfumarat p nyrene ikke utelukkes.</span>
                                    </p>
                                    <p style="line-height:normal" class="MsoNormal"/>
                                    <p style="line-height:normal" class="MsoNormal"/>
                                </div>
              </text>
            </section>
          </section>
          <section id="d3f0286b-3050-4928-b713-0294beb4cb15">
            <title value="6.       FARMAS&#xD8;YTISKE OPPLYSNINGER"/>
            <code>
              <coding>
                <system value="http://spor.ema.europa.eu/v1/example-sections"/>
                <code value="47"/>
                <display value="6. FARMAS&#xD8;YTISKE OPPLYSNINGER"/>
              </coding>
            </code>
            <text>
              <status value="additional"/><div xmlns="http://www.w3.org/1999/xhtml">
                                <p style="line-height:normal;page-break-after:avoid" class="MsoNormal"/>
                                <p style="line-height:normal;page-break-after:avoid" class="MsoNormal">
                                    <b>
                                        <span lang="NO-BOK">6.1     Fortegnelse over hjelpestoffer</span>
                                    </b>
                                </p>
                                <p style="line-height:normal;page-break-after:avoid" class="MsoNormal"/>
                                <p style="line-height:normal;page-break-after:avoid" class="MsoNormal">
                                    <u>
                                        <span lang="NO-BOK">Acme Product 30 mg og Acme Product 120 mg</span>
                                    </u>
                                </p>
                                <p style="line-height:normal;page-break-after:avoid" class="MsoNormal">
                                    <i>
                                        <span lang="NO-BOK">Kjerne:</span>
                                    </i>
                                </p>
                                <p style="line-height:normal;page-break-after:avoid" class="MsoNormal">
                                    <span lang="NO-BOK">Laktosemonohydrat</span>
                                </p>
                                <p style="line-height:normal" class="MsoNormal">
                                    <span lang="NO-BOK">Mikrokrystallinsk cellulose</span>
                                </p>
                                <p style="line-height:normal" class="MsoNormal">
                                    <span lang="NO-BOK">Krysskarmellosenatrium</span>
                                </p>
                                <p style="line-height:normal" class="MsoNormal">
                                    <span lang="NO-BOK">Kolloidal vannfri silika</span>
                                </p>
                                <p style="line-height:normal" class="MsoNormal">
                                    <span lang="NO-BOK">Magnesiumstearat</span>
                                </p>
                                <p style="line-height:normal" class="MsoNormal"/>
                                <p style="line-height:normal;page-break-after:avoid" class="MsoNormal">
                                    <u>
                                        <span lang="NO-BOK">Acme Product 30 mg</span>
                                    </u>
                                </p>
                                <p style="line-height:normal;page-break-after:avoid" class="MsoNormal">
                                    <i>
                                        <span lang="NO-BOK">Drasjering:</span>
                                    </i>
                                </p>
                                <p style="line-height:normal;page-break-after:avoid" class="MsoNormal">
                                    <span lang="NO-BOK">Metakrylsyreetylakrylatkopolymer (1:1) </span>
                                </p>
                                <p style="line-height:normal" class="MsoNormal">
                                    <span lang="NO-BOK">Talkum</span>
                                </p>
                                <p style="line-height:normal" class="MsoNormal">
                                    <span lang="NO-BOK">Trietylsitrat</span>
                                </p>
                                <p style="line-height:normal" class="MsoNormal">
                                    <span lang="NO-BOK">Titandioksid (E171)</span>
                                </p>
                                <p style="line-height:normal" class="MsoNormal">
                                    <span lang="NO-BOK">Simetikon</span>
                                </p>
                                <p style="line-height:normal" class="MsoNormal"/>
                                <p style="line-height:normal;page-break-after:avoid" class="MsoNormal">
                                    <u>
                                        <span lang="NO-BOK">Acme Product 120 mg</span>
                                    </u>
                                </p>
                                <p style="line-height:normal;page-break-after:avoid" class="MsoNormal">
                                    <i>
                                        <span lang="NO-BOK">Drasjering:</span>
                                    </i>
                                </p>
                                <p style="line-height:normal;page-break-after:avoid" class="MsoNormal">
                                    <span lang="NO-BOK">Metakrylsyreetylakrylatkopolymer (1:1) </span>
                                </p>
                                <p style="line-height:normal" class="MsoNormal">
                                    <span lang="NO-BOK">Talkum</span>
                                </p>
                                <p style="line-height:normal" class="MsoNormal">
                                    <span lang="NO-BOK">Trietylsitrat</span>
                                </p>
                                <p style="line-height:normal" class="MsoNormal">
                                    <span lang="NO-BOK">Titandioksid (E171)</span>
                                </p>
                                <p style="line-height:normal" class="MsoNormal">
                                    <span lang="NO-BOK">Simetikon</span>
                                </p>
                                <p style="line-height:normal" class="MsoNormal">
                                    <span lang="NO-BOK">Indigokarmin (E132)</span>
                                </p>
                                <p style="line-height:normal" class="MsoNormal">
                                    <span lang="NO-BOK">Natriumhydroksid</span>
                                </p>
                                <p style="line-height:normal" class="MsoNormal"/>
                            </div>
            </text>
            <section id="9c73367e-0062-48a7-a22c-325e1df72da9">
              <title value="6.2     Uforlikeligheter"/>
              <code>
                <coding>
                  <system value="http://spor.ema.europa.eu/v1/example-sections"/>
                  <code value="49"/>
                  <display value="6.2 Uforlikeligheter"/>
                </coding>
              </code>
              <text>
                <status value="additional"/><div xmlns="http://www.w3.org/1999/xhtml">
                                    <p style="line-height:normal;page-break-after:avoid" class="MsoNormal"/>
                                    <p style="line-height:normal;page-break-after:avoid" class="MsoNormal">
                                        <span lang="NO-BOK">Ikke relevant.</span>
                                    </p>
                                    <p style="line-height:normal" class="MsoNormal"/>
                                </div>
              </text>
            </section>
            <section id="c5de1b87-c384-4acd-b513-358efd62c979">
              <title value="6.3     Holdbarhet"/>
              <code>
                <coding>
                  <system value="http://spor.ema.europa.eu/v1/example-sections"/>
                  <code value="50"/>
                  <display value="6.3 Holdbarhet"/>
                </coding>
              </code>
              <text>
                <status value="additional"/><div xmlns="http://www.w3.org/1999/xhtml">
                                    <p style="line-height:normal;page-break-after:avoid" class="MsoNormal"/>
                                    <p style="line-height:normal;page-break-after:avoid" class="MsoNormal">
                                        <span lang="NO-BOK">3 r.</span>
                                    </p>
                                    <p style="line-height:normal" class="MsoNormal"/>
                                </div>
              </text>
            </section>
            <section id="09bc5d7a-aa2b-4030-bbf0-186dc3872257">
              <title value="6.4     Oppbevaringsbetingelser"/>
              <code>
                <coding>
                  <system value="http://spor.ema.europa.eu/v1/example-sections"/>
                  <code value="51"/>
                  <display value="6.4 Oppbevaringsbetingelser"/>
                </coding>
              </code>
              <text>
                <status value="additional"/><div xmlns="http://www.w3.org/1999/xhtml">
                                    <p style="line-height:normal;page-break-after:avoid" class="MsoNormal"/>
                                    <p style="line-height:normal;page-break-after:avoid" class="MsoNormal">
                                        <span lang="NO-BOK">Dette legemidlet krever ingen spesielle oppbevaringsbetingelser.</span>
                                    </p>
                                    <p style="line-height:normal" class="MsoNormal"/>
                                </div>
              </text>
            </section>
            <section id="788b714e-99f5-4838-9d3d-c2278e3e5f06">
              <title value="6.5     Emballasje (type og innhold)"/>
              <code>
                <coding>
                  <system value="http://spor.ema.europa.eu/v1/example-sections"/>
                  <code value="52"/>
                  <display value="6.5 Emballasje (type og innhold) &lt;og spesielt utstyr for bruk, administrering eller implantasjon&gt;"/>
                </coding>
              </code>
              <text>
                <status value="additional"/><div xmlns="http://www.w3.org/1999/xhtml">
                                    <p style="line-height:normal;page-break-after:avoid" class="MsoNormal"/>
                                    <p style="line-height:normal;page-break-after:avoid" class="MsoNormal">
                                        <u>
                                            <span lang="NO-BOK">Acme Product 30 mg</span>
                                        </u>
                                    </p>
                                    <p style="line-height:normal;page-break-after:avoid" class="MsoNormal">
                                        <span lang="NO-BOK">42, 70 og 210 enterotabletter i PVC/PVDC blisterpakninger av aluminium. </span>
                                    </p>
                                    <p style="line-height:normal" class="MsoNormal"/>
                                    <p style="line-height:normal;page-break-after:avoid" class="MsoNormal">
                                        <u>
                                            <span lang="NO-BOK">Acme Product 120 mg</span>
                                        </u>
                                    </p>
                                    <p style="line-height:normal;page-break-after:avoid" class="MsoNormal">
                                        <span lang="NO-BOK">40, 70, 90, 100, 120, 180, 200, 240, 300, 360 og 400 enterotabletter i PVC/PVDC blisterpakninger av aluminium.</span>
                                    </p>
                                    <p style="line-height:normal" class="MsoNormal"/>
                                    <p style="line-height:normal" class="MsoNormal">
                                        <span lang="NO-BOK">Ikke alle pakningsstrrelser vil ndvendigvis bli markedsfrt.</span>
                                    </p>
                                    <p style="line-height:normal" class="MsoNormal"/>
                                </div>
              </text>
            </section>
            <section id="08b14b4e-bbe6-426c-be2c-0c9e1b6b6347">
              <title value="6.6     Spesielle forholdsregler for destruksjon"/>
              <code>
                <coding>
                  <system value="http://spor.ema.europa.eu/v1/example-sections"/>
                  <code value="53"/>
                  <display value="6.6 Spesielle forholdsregler for destruksjon &lt;og annen h&#xE5;ndtering&gt;"/>
                </coding>
              </code>
              <text>
                <status value="additional"/><div xmlns="http://www.w3.org/1999/xhtml">
                                    <p style="line-height:normal;page-break-after:avoid" class="MsoNormal"/>
                                    <p style="line-height:normal;page-break-after:avoid" class="MsoNormal">
                                        <span lang="NO-BOK">Ingen spesielle forholdsregler for destruksjon.</span>
                                    </p>
                                    <p style="line-height:normal" class="MsoNormal"/>
                                    <p style="line-height:normal" class="MsoNormal"/>
                                </div>
              </text>
            </section>
          </section>
          <section id="ab1e079a-7e7b-459a-9687-94a2a7b20abe">
            <title value="7.       INNEHAVER AV MARKEDSF&#xD8;RINGSTILLATELSEN"/>
            <code>
              <coding>
                <system value="http://spor.ema.europa.eu/v1/example-sections"/>
                <code value="55"/>
                <display value="7. INNEHAVER AV MARKEDSF&#xD8;RINGSTILLATELSEN"/>
              </coding>
            </code>
            <text>
              <status value="additional"/><div xmlns="http://www.w3.org/1999/xhtml">
                                <p style="line-height:normal;page-break-after:avoid" class="MsoNormal"/>
                                <p style="line-height:normal;page-break-after:avoid" class="MsoNormal">
                                    <span lang="NO-BOK">Almirall, S.A.</span>
                                </p>
                                <p style="line-height:normal;page-break-after:avoid" class="MsoNormal">
                                    <span lang="NO-BOK">Ronda General Mitre, 151</span>
                                </p>
                                <p style="line-height:normal;page-break-after:avoid" class="MsoNormal">
                                    <span lang="NO-BOK">08022 Barcelona</span>
                                </p>
                                <p style="line-height:normal;page-break-after:avoid" class="MsoNormal">
                                    <span lang="NO-BOK">Spania</span>
                                </p>
                                <p style="line-height:normal" class="MsoNormal"/>
                                <p style="line-height:normal" class="MsoNormal"/>
                            </div>
            </text>
          </section>
          <section id="e2f48221-aa2b-4a2a-828a-6a1fe1926ff8">
            <title value="8.       MARKEDSF&#xD8;RINGSTILLATELSESNUMMER (NUMRE)"/>
            <code>
              <coding>
                <system value="http://spor.ema.europa.eu/v1/example-sections"/>
                <code value="56"/>
                <display value="8. MARKEDSF&#xD8;RINGSTILLATELSESNUMMER (NUMRE)"/>
              </coding>
            </code>
            <text>
              <status value="additional"/><div xmlns="http://www.w3.org/1999/xhtml">
                                <p style="line-height:normal;page-break-after:avoid" class="MsoNormal"/>
                                <p style="line-height:normal" class="MsoNormal">
                                    <span lang="ES">EU/1/17/1201/001
                                        <br/>
EU/1/17/1201/002
                                        <br/>
EU/1/17/1201/003
                                        <br/>
EU/1/17/1201/004
                                        <br/>
EU/1/17/1201/005
                                        <br/>
EU/1/17/1201/006
                                        <br/>
                                    </span>
                                    <span lang="ES">EU/1/17/1201/007
                                        <br/>
                                    </span>
                                    <span lang="ES">EU/1/17/1201/008
                                        <br/>
EU/1/17/1201/009
                                        <br/>
                                    </span>
                                    <span lang="ES">EU/1/17/1201/010
                                        <br/>
EU/1/17/1201/011
                                    </span>
                                </p>
                                <p style="line-height:normal" class="MsoNormal">
                                    <span lang="ES">EU/1/17/1201/012</span>
                                </p>
                                <p style="line-height:normal" class="MsoNormal">
                                    <span lang="ES">EU/1/17/1201/013</span>
                                </p>
                                <p style="line-height:normal" class="MsoNormal">
                                    <span lang="ES">EU/1/17/1201/014</span>
                                </p>
                                <p style="line-height:normal" class="MsoNormal"/>
                                <p style="line-height:normal" class="MsoNormal"/>
                                <p style="line-height:normal" class="MsoNormal"/>
                            </div>
            </text>
          </section>
          <section id="5b69e508-14f8-46fe-8eb4-e9bc863b2fd7">
            <title value="9.       DATO FOR F&#xD8;RSTE MARKEDSF&#xD8;RINGSTILLATELSE /SISTE FORNYELSE"/>
            <code>
              <coding>
                <system value="http://spor.ema.europa.eu/v1/example-sections"/>
                <code value="57"/>
                <display value="9. DATO FOR F&#xD8;RSTE MARKEDSF&#xD8;RINGSTILLATELSE / SISTE FORNYELSE"/>
              </coding>
            </code>
            <text>
              <status value="additional"/><div xmlns="http://www.w3.org/1999/xhtml">
                                <p style="line-height:normal;page-break-after:avoid" class="MsoNormal"/>
                                <p style="line-height:normal;page-break-after:avoid" class="MsoNormal">
                                    <span lang="NO-BOK">Dato for frste markedsfringstillatelse: 23. juni 2017</span>
                                </p>
                                <p style="line-height:normal" class="MsoNormal"/>
                                <p style="line-height:normal" class="MsoNormal"/>
                            </div>
            </text>
          </section>
          <section id="0293fe81-3702-4b3b-94fa-4c478cfb6da6">
            <title value="10.     OPPDATERINGSDATO"/>
            <code>
              <coding>
                <system value="http://spor.ema.europa.eu/v1/example-sections"/>
                <code value="58"/>
                <display value="10. OPPDATERINGSDATO"/>
              </coding>
            </code>
            <text>
              <status value="additional"/><div xmlns="http://www.w3.org/1999/xhtml">
                                <p style="line-height:normal;page-break-after:avoid" class="MsoNormal"/>
                                <p style="line-height:normal;page-break-after:avoid" class="MsoNormal">
                                    <span lang="NO-BOK">Detaljert informasjon er tilgjengelig p nettstedet til Det europeiske legemiddelkontoret (The European Medicines Agency) </span>
                                    <span lang="EN-GB">
                                        <a href="http://www.ema.europa.eu">
                                            <span lang="NO-BOK">http://www.ema.europa.eu</span>
                                        </a>
                                    </span>
                                    <span style="color:blue" lang="NO-BOK">.</span>
                                </p>
                                <p style="margin-right:-.1pt;line-height:normal" class="MsoNormal"/>
                                <span style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;,serif" lang="NO-BOK">
                                    <br clear="all" style="page-break-before:always"/>
                                </span>
                            </div>
            </text>
          </section>
        </section>
      </Composition>
    </resource>
  </entry>
</Bundle>